

Vietnam Quality of TB Services Assessment (QTSA)

Compiled Tables of Results

October 2024



This publication was produced with the support of the United States Agency for International Development (USAID) under the terms of the TB Data, Impact Assessment and Communications Hub (TB DIAH) Associate Award No. 7200AA18LA00007. TB DIAH is implemented by the University of North Carolina at Chapel Hill, in partnership with John Snow, Inc. Views expressed are not necessarily those of USAID or the United States government. TL-24-113

Vietnam Quality of TB Services Assessment (QTSA)

Compiled Tables of Results

TB DIAH

University of North Carolina
123 West Franklin Street, Suite 330
Chapel Hill, North Carolina 27516 USA
Phone: 919-445-69495

hub@tbdiah.org
www.tbdiah.org



Table of Contents

Vietnam Quality of TB Services Assessment (QTSA)	0
Table of Contents	0
Preliminary Results	4
1. Sample Characteristics	4
1.1. Facility Characteristics	4
1.1.1. Facility levels, management authority, and location	4
1.1.2. Facility General Services, Caseloads	6
1.2. Provider Characteristics	8
1.3. Patient Characteristics	9
2. Structural Indicators	12
2.1. Availability of TB Services	12
2.1.1. Screening Services	12
2.1.2. Diagnostic Services	13
2.1.3. Treatment Services	15
2.1.4 Pediatric Services	20
2.1.5 LTBI Services	22
2.1.6. Contact Investigation Services	24
2.1.7. TB-HIV Linkages	25
2.1.8. CHW services	26
2.1.9. CHW management	27
2.2. Laboratory Infrastructure	28
2.2.1. Specimen Management and Transport (onsite laboratories)	28
2.2.2. Offsite Laboratories	30
2.2.3. Quality Assurance	32
2.3. Medical Equipment and Drug Availability	33
2.3.1. Basic TB Care equipment Availability	33
2.3.2. Laboratory Equipment Availability (for facilities with onsite lab)	34
2.3.3. Drug Availability	36
2.4. Storage Conditions	43
2.5. Infection Prevention and Control	44
2.5.1. IPC Practices	44
2.5.2. IPC Infrastructure	45
2.5.3. TB screening of facility Staff	47
2.6. Management of TB Services	48
2.6.1. Availability of Guidelines, Protocols, etc.	48

2.6.2	Supervision and Feedback for Facility/Providers	51
2.7.	Capacity of TB Providers	52
2.7.1.	Training –Facility Perspective	52
2.7.2.	Training –TB Provider Perspective	53
2.8.	Health Insurance Reimbursement Coverage	60
2.8.1.	Service coverage (by health insurance scheme)	60
2.8.2.	Changes noticed since implementation of HI at health facility	63
2.8.3.	Challenges of Health Insurance Scheme experienced by Health Facility	64
3	Process Indicators	65
3.1.	Provider TB Casement Management	65
3.1.1.	Establishing Patient Rapport	65
3.1.2.	Patient Assessment	65
3.2.	TB Provider Knowledge & Practice	66
3.3.	Patient-Provider Interactions	67
3.3.1.	Patient Experience at Health Facility	67
3.3.2.	Information provided to TB patients (provider perspective)	70
3.3.3.	Information provided to TB patients (patient perspective)	74
3.3.4.	Treatment Supporters	76
3.4.	Patient Knowledge of TB	77
3.4.1.	Cause, Modes of Transmission, and Risk Factors of TB	77
3.4.2.	TB Symptoms	82
3.4.3.	Side Effects of TB Drugs	85
3.5.	TB Stigma	88
3.6.	Patient Barriers to Accessing TB Care	89
3.7.	Patient Satisfaction with TB Services	91
3.7.1.	Patient Perspective of TB Services offered by Health Facility	91
3.7.2.	General Satisfaction	92
4	Outcome Indicators	93
4.1.	Timing of Care Seeking, Diagnosis and Treatment Initiation	93
4.2.	TB Treatment Outcomes	94
4.2.1.	DS-TB Outcomes	94
4.2.2.	DR-TB Outcomes	94
4.3.	TPT Outcomes	95
4.3.1.	PLHIV	95
4.3.2.	Children under 5 years of age	95

Preliminary Results

Table Key: Data tables are color-coded based on the tool that was used to capture the information and illustrated by the figure below.



1. Sample Characteristics

1.1. Facility Characteristics

1.1.1. Facility levels, management authority, and location

Table 1.1.1a

Facility Type	No.	%
District general hospital	8	4.4
District Preventive Health Center (one function)	28	15.6
District Health Center (two-function)	127	70.6
CDC	3	1.7
Lung hospital	13	7.2
Other (Provincial General Hospital)	1	0.6
Total	180	100

Table 1.1.1b

Facility Management Authority	No.	%
Government/public	179	99.4
Military/paramilitary	1	0.6
Total	180	100

Table 1.1.1c

Facility Location	No.	%
Urban	64	35.6
Peri-urban	14	7.8
Rural	102	56.7
Total	180	100

Table 1.1.1d

Type of Facility	Facility Location						Total	
	Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%
District general hospital	2	3.1	1	7.1	5	4.9	8	4.4
District preventive health center (one function)	9	14.1	1	7.1	18	17.6	28	15.6
District health center (two-function)	38	59.4	12	85.7	77	75.5	127	70.6
CDC	3	4.7	0	0	0	0	3	1.7
Lung hospital	11	17.2	0	0	2	2	13	7.2
Other, (Provincial General Hospital)	1	1.6	0	0	0	0	1	0.6
Total	64	100	14	100	102	100	180	100

Table 1.1.1e

Facility Management Authority	Facility Location						Total	
	Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%
Government/public	64	100	14	100	101	99	179	99.4
Military/paramilitary	0	0	0	0	1	1	1	0.6
Total	64	100	14	100	102	100	180	100

1.1.2. Facility General Services, Caseloads

Table 1.1.2a

1.1.4 Type of Services Offered	No.	%
Outpatient only	58	32.2
Both inpatient and outpatient	122	67.8
Total	180	100

Table 1.1.2b

1.1.5 TB services covered by the HI scheme at this facility	No.	%
Yes	152	84.4
No	28	15.6
Total	180	100

Table 1.1.2c

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Outpatient only	0	0	28	100	27	21.3	3	100	0	0	0	0	25	39.1	7	50	26	25.5	58	32.2
Both inpatient and outpatient	8	100	0	0	100	78.7	0	0	13	100	1	100	39	60.9	7	50	76	74.5	122	67.8
Total	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100

Table 1.1.2d

	Facility Type						Facility Location			Total
	District General Hospital	District Preventive Health Center (one function)	District Health Center (two-function)	CDC	Lung Hospital	Provincial General Hospital	Urban	Peri-urban	Rural	
Median	8,500	100	5,500	1,309	1,020	data not available	2,974	2,500	4,200	3,231
Range	[2,00 - 25,000]	[3 - 2,947]	[3 - 22,803]	[1,222 - 3,254]	[200 - 3,500]	data not available	[15 - 25,000]	[0 - 15,000]	[3 - 22,083]	[3 - 25,000]
Total Facilities	8	28	127	3	13	1	64	14	102	180
Median	150	7	80	150	331	data not available	120	100	47	60
Range	[8 - 300]	[0 - 160]	[2 - 1,400]	[22 - 170]	[60 - 2,450]	data not available	[2 - 2,450]	[0 - 660]	[0 - 1,400]	[0 - 2,450]
Total Facilities	8	28	127	3	13	1	64	14	102	180

1.2. Provider Characteristics

Table 1.2a

	Facility Type												Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
1.1 Provider sex (n=376)														
Male	14	63.6	25	69.4	133	50	3	60	16	36.4	1	33.3	192	51.1
Female	8	36.4	11	30.6	133	50	2	40	28	63.6	2	66.7	184	48.9
Total	22	100	36	100	266	100	5	100	44	100	3	100	376	100
1.4 How would you best describe your current occupational category at this facility? (n=376)														
Nurse	8	36.4	0	0	56	21.1	0	0	14	31.8	1	33.3	79	21
Medical doctor/clinical officer	14	63.6	25	69.4	181	68	4	80	29	65.9	2	66.7	255	67.8
Other (specify)	0	0	11	30.6	29	10.9	1	20	1	2.3	0	0	42	11.2
1.9 Approximately, how many patients do you personally se or care for in this facility in a typical week? (n=376)														
1-50	4	18.2	27	75	114	42.9	5	100	15	34.1	1	33.3	166	44.1
51-100	4	18.2	2	5.6	62	23.3	0	0	9	20.5	2	66.7	79	21
101-150	4	18.2	0	0	28	10.5	0	0	11	25	0	43	11.4	
151-200	3	13.6	0	0	19	7.1	0	0	7	15.9	0	0	29	7.7
201-250	2	9.1	0	0	10	3.8	0	0	0	0	0	0	12	3.2
251-300	3	13.6	1	2.8	10	3.8	0	0	1	2.3	0	0	15	4
More than 300	2	9.1	0	0	23	8.6	0	0	1	2.3	0	26	6.9	
Don't know	0	0	6	16.7	0	0	0	0	0	0	0	0	6	1.6
Total	22	100	36	100	266	100	5	100	44	100	3	100	376	100

1.3. Patient Characteristics

Table 1.3a

Patient Characteristics	No.	%
022. Have you been diagnosed with TB or are you being treated for TB at this facility? If so, what type of TB do you have?		
Yes, drug susceptible TB	641	92.1
Yes, drug resistant TB	55	7.9
Total	696	100

Table 1.3b

Table 1:55

Patient Characteristics by Type of TB	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
1.1 Sex of patient (n=696)						
Male	478	74.6	48	87.3	526	75.6
Female	163	25.4	7	12.7	170	24.4
1.2.1 Patient age group (n=696)						
<24	38	6	0	0	38	5.4
25-34	69	11	10	17.1	79	11.2
35-44	106	16.6	15	25.8	121	17.2
45-54	146	22.8	16	27.5	162	23.2
55+	280	43.9	17	29.1	297	42.5
1.3 What is the highest level of education you have completed? (n=696)						
Under primary	97	15.1	10	18.2	107	15.4
Primary education	151	23.6	15	27.3	166	23.9
Lower secondary education	205	32	19	34.5	224	32.2
Upper secondary education	119	18.6	7	12.7	126	18.1
Postsecondary education	67	10.5	4	7.3	71	10.2
No response	2	0.3	0	0	2	0.3

1.5 Do you live in an urban or rural area? (n=696)						
Urban	215	33.5	24	43.6	239	34.3
Rural	426	66.5	31	56.4	457	65.7
1.6 What is your employment status? (n=696)						
Employed full time	258	40.2	18	32.7	276	39.7
Employed part time	78	12.2	7	12.7	85	12.2
Self employed	38	5.9	4	7.3	42	6
Unemployed	74	11.5	11	20	85	12.2
Housewife	70	10.9	8	14.5	78	11.2
Retired	103	16.1	4	7.3	107	15.4
Student	7	1.1	0	0	7	1
No response	13	2	3	5.5	16	2.3
1.9 What type of transportation do you use most often to get to this facility? (n=696)						
Bicycle	20	3.1	3	5.5	23	3.3
Bus	12	1.9	0	0	12	1.7
Car	15	2.3	2	3.6	17	2.4
Motorcycle (personal)	576	89.9	49	89.1	625	89.8
Taxi	3	0.5	0	0	3	0.4
Walking	11	1.7	0	0	11	1.6
Other (specify)	4	0.6	1	1.8	5	0.7
Total	641	100	55	100	696	100
1.9 On average, how long does it take you to get to this facility from your home using your usual method of transportation you just listed? (Hours) (n=696)						
0 Hours	599	93.4	43	78.2	642	92.2
1 Hour	30	4.7	10	18.2	40	5.7
2 Hours	7	1.1	1	1.8	8	1.1
3 Hours	1	0.2	1	1.8	2	0.3
4 Hours	1	0.2	0	0	1	0.1
15 Hours	1	0.2	0	0	1	0.1
Don't know	2	0.3	0	0	2	0.3

2.6 What phase of treatment are you in now? (n=696)						
Intensive	160	25	6	10.9	166	23.9
Continuation	439	68.5	45	81.8	484	69.5
Don't know	42	6.6	4	7.3	46	6.6

2. Structural Indicators

2.1. Availability of TB Services

2.1.1. Screening Services

Table 2.1.1a

Table 2.1.1.2

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.1 Facility provides any form of TB screening (n=180)	8	100	20	71.4	125	98.4	3	100	13	100	1	100	63	98.4	14	100	93	91.2	170	94.4
3.1.1 Screening for TB by clinical symptoms and signs (n=170)	8	100	16	80	124	99.2	3	100	13	100	1	100	62	98.4	14	100	89	95.7	165	97.1
3.1.2 Screening for TB by X-ray (n=170)	8	100	4	20	121	96.8	2	66.7	13	100	1	100	54	85.7	13	92.9	82	88.2	149	87.6
3.1.3 Presumptive TB patients charged a fee for screening X-rays (n=149)	7	87.5	3	75	79	65.3	2	100	9	69.2	1	100	43	79.6	10	76.9	48	58.5	101	67.8

2.1.2. Diagnostic Services

Table 2.1.2a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.2 Facility provides TB diagnosis services (n=180)	8	100	15	53.6	125	98.4	3	100	13	100	1	100	60	93.8	13	92.9	92	90.2	165	91.7
TB screening and diagnostic services offered by health facilities (n=165)																				
3.1.4 Diagnosis of TB by clinical symptoms and signs	8	100	4	26.7	107	85.6	3	100	13	100	1	100	51	85	13	100	72	78.3	136	82.4
3.1.5 Diagnosis of TB by X-ray	8	100	0	0	113	90.4	2	66.7	13	100	1	100	50	83.3	13	100	74	80.4	137	83
3.1.6 Diagnosis of TB by smear microscopy	6	75	14	93.3	124	99.2	3	100	13	100	1	100	60	100	13	100	88	95.7	161	97.6
3.1.7 Diagnosis of TB by culture (solid or liquid)	1	12.5	3	20	41	32.8	2	66.7	11	84.6	0	0	27	45	5	38.5	26	28.3	58	35.2
3.1.8 Diagnosis of TB by GeneXpert	4	50	11	73.3	89	71.2	3	100	13	100	0	0	46	76.7	11	84.6	63	68.5	120	72.7
3.1.9 Diagnosis of TB by urine LAM	0	0	0	0	5	4	1	33.3	2	15.4	0	0	6	10	0	0	2	2.2	8	4.8
3.1.10 Diagnosis of TB in children using stool-based testing	0	0	3	20	16	12.8	2	66.7	8	61.5	0	0	17	28.3	1	7.7	11	12	29	17.6
3.1.11 Diagnosis of TB by Fine Needle Aspiration Cytology (FNAC)	0	0	0	0	2	1.6	1	33.3	9	69.2	1	100	11	18.3	0	0	2	2.2	13	7.9
3.1.12 Diagnosis of TBM by testing CSF	0	0	0	0	0	0	1	33.3	7	53.8	1	100	9	15	0	0	0	0	9	5.5
3.1.13 Diagnosis of TBM by TrueNat	0	0	0	0	2	1.6	0	0	7	53.8	0	0	8	13.3	0	0	1	1.1	9	5.5
3.1.14 Diagnosis of TBM by LPA	0	0	0	0	1	0.8	1	33.3	5	38.5	0	0	6	10	0	0	1	1.1	7	4.2

Table 2.1.2b

Onsite Diagnostics	Facility Type												Facility Location								Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two- function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural					
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
3.1.20 Facility referred patients elsewhere for TB diagnosis, either via smear microscopy or GeneXpert in the past 6 months (n=48)	4	100	2	28.6	34	94.4	--	--	--	--	1	100	14	93.3	2	100	25	80.6	41	85.4		
2.3 X-ray onsite (n=180)	8	100	5	17.9	125	98.4	2	66.7	13	100	1	100	56	87.5	13	92.9	85	83.3	154	85.6		
2.2.2 Laboratory for TB diagnosis (n=165)	6	75	13	86.7	124	99.2	3	100	13	100	1	100	59	98.3	13	100	88	95.7	160	97		
3.1.17 GeneXpert unit on-site (n=120)	1	25	2	18.2	14	15.7	3	100	13	100	--	--	24	52.2	1	9.1	8	12.7	33	27.5		
3.1.18 Type of GeneXpert Cartridges Available (n=33)																						
Xpert MTB/RIF	1	100	2	100	4	28.6	2	66.7	1	7.7	--	--	7	29.2	0	0	3	37.5	10	30.3		
Xpert Ultra	1	100	1	50	6	42.9	1	33.3	2	15.4	--	--	8	33.3	0	37.5	11	33.3				
Xpert MTB/RIF Ultra	1	100	1	50	6	42.9	1	33.3	2	15.4			8	33.3	0	0	3	37.5	11	33.3		
Xpert MTB/XDR	0	0	0	0	7	50	3	100	11	84.6			15	62.5	1	100	5	62.5	21	63.6		
Total	1	100	2	100	14	100	3	100	13	100	--	--	24	100	1	100	8	100	33	100		

Table 2.1.2c

Drug Susceptibility Testing	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
3.2.1 First-line drug susceptibility testing available (n=165)	0	0	0	0	8	6.4	1	33.3	4	30.8	0	0	9	15	0	0	4	4.3	13	7.9
3.2.2 Second-line drug susceptibility testing available (n=165)	0	0	0	0	2	1.6	1	33.3	2	15.4	0	0	5	8.3	0	0	0	0	5	3
3.2.3 Facility has referred patients elsewhere for DR-TB diagnosis in the past 6 months (n=160)	4	50	1	6.7	84	68.3	1	50	8	72.7	1	100	38	69.1	8	61.5	53	57.6	99	61.9

2.1.3. Treatment Services

Table 2.1.3a

Table 2.1.3d

DS-TB Treatment Services	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.5 Facility prescribe treatment for TB or manage patients with TB (n=180)	8	100	23	82.1	126	99.2	3	100	13	100	1	100	62	96.9	13	92.9	99	97.1	174	96.7
Types of Treatment Services Provided (n=174)																				
6.1.1 Prescription of drugs for TB treatment	6	75	9	39.1	120	95.2	2	66.7	13	100	1	100	54	87.1	13	100	84	84.8	151	86.8
6.1.2 TB treatment and follow-up during the intensive phase	8	100	12	52.2	122	96.8	3	100	13	100	1	100	57	91.9	13	100	89	89.9	159	91.4

6.1.3 TB treatment and follow-up during the continuation phase	8	100	16	69.6	121	96	3	100	13	100	1	100	59	95.2	13	100	90	90.9	162	93.1
6.1.4 Facility-based direct observation of treatment (DOT)	1	12.5	2	8.7	74	58.7	0	0	11	84.6	1	100	31	50	6	46.2	52	52.5	89	51.1
6.1.5 Community-based DOT	2	25	17	73.9	93	73.8	1	33.3	7	53.8	0	0	38	61.3	7	53.8	75	75.8	120	69
6.1.6 Video DOT	0	0	0	0	8	6.3	0	0	2	15.4	0	0	5	8.1	1	7.7	4	4	10	5.7
6.1.7 Home-based treatment	1	12.5	5	21.7	69	54.8	1	33.3	6	46.2	0	0	25	40.3	4	30.8	53	53.5	82	47.1
6.1.8 Reminder phone calls or SMS texts to support patient's adherence to treatment	5	62.5	15	65.2	115	91.3	2	66.7	9	69.2	1	100	52	83.9	10	76.9	85	85.9	147	84.5
6.1.9 Psychosocial or other adherence support	4	50	13	56.5	94	74.6	2	66.7	9	69.2	1	100	44	71	9	69.2	70	70.7	123	70.7
6.1.10 Nutritional support or meals for TB patients	1	12.5	0	0	16	12.7	0	0	10	76.9	1	100	14	22.6	4	30.8	10	10.1	28	16.1
6.1.11 Support group for TB patients	1	12.5	0	0	23	18.3	0	0	5	38.5	0	0	13	21	4	30.8	12	12.1	29	16.7
6.1.12 Patient tracking of those who miss an appointment	5	62.5	12	52.2	113	89.7	2	66.7	12	92.3	1	100	52	83.9	12	92.3	81	81.8	145	83.3
Total	8	100	23	100	126	100	3	100	13	100	1	100	62	100	13	100	99	100	174	100

Table 2.1.3b

Table 2.1.5b

Information provided by facility staff to TB patients (n=174)	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
6.3.1(a) What test results mean	8	100	20	87	126	100	3	100	13	100	1	100	61	98.4	13	100	97	98	171	98.3
6.3.2(a) How TB is spread to others	8	100	21	91.3	125	99.2	3	100	13	100	1	100	62	100	13	100	96	97	171	98.3

6.3.3(a) The need for a treatment supporter	8	100	20	87	109	86.5	2	66.7	11	84.6	0	0	55	88.7	13	100	82	82.8	150	86.2
6.3.4(a) How TB medication should be taken, e.g., dosage, frequency, etc.	8	100	21	91.3	125	99.2	2	66.7	13	100	1	100	61	98.4	13	100	96	97	170	97.7
6.3.5(a) The importance of treatment adherence	8	100	21	91.3	126	100	2	66.7	13	100	1	100	61	98.4	13	100	97	98	171	98.3
6.3.6(a) Options available for treatment support, e.g., DOT	8	100	13	56.5	102	81	2	66.7	13	100	0	0	52	83.9	12	92.3	74	74.7	138	79.3
6.3.7(a) What to do when experiencing side effects and/or AEs	8	100	21	91.3	126	100	2	66.7	13	100	1	100	61	98.4	13	100	97	98	171	98.3
6.3.8(a) What to do if they run out of medicines	6	75	15	65.2	94	74.6	2	66.7	12	92.3	1	100	49	79	9	69.2	72	72.7	130	74.7
6.3.9(a) What to do if they need to leave for more than a month to an area beyond the catchment of the health facility	7	87.5	17	73.9	113	89.7	2	66.7	13	100	1	100	55	88.7	13	100	85	85.9	153	87.9
Total	8	100	23	100	126	100	3	100	13	100	1	100	62	100	13	100	99	100	174	100

Table 2.1.3c

Other Treatment Information	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
6.2.1 Does this facility assess the progress of each TB patient registered (n=174)	8	100	15	65.2	120	95.2	2	66.7	13	100	1	100	57	91.9	13	100	89	89.9	159	91.4
6.2.2 Do you ask patients about symptoms of drug side	8	100	16	69.6	126	100	2	66.7	13	100	1	100	59	95.2	13	100	94	94.9	166	95.4

effects and/or adverse events (n=174)																				
6.2.3 Do you distribute ancillary medications to treat/manage side effects (n=174)	6	75	2	8.7	76	60.3	2	66.7	12	92.3	1	100	40	64.5	6	46.2	53	53.5	99	56.9
2.7 (a) Has this facility referred TB patients elsewhere for management of other medical conditions (n=180)	1	12.5	7	25	71	55.9	2	66.7	13	100	0	0	40	62.5	4	28.6	50	49	94	52.2
2.5.1 Are patients charged a fee for TB medicines? (inclusive of facilities where TB services are not covered by the national HI scheme) (n=23)	--	--	2	10	1	100	0	0	--	--	--	--	1	12.5	--	--	2	13.3	3	13

Table 2.1.3d

DR-TB Treatment Services	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.5.3 Facility Provides DR-TB Treatment (n=174)	4	2.7	19	12.7	111	74	3	2	13	8.7	--	--	56	37.3	10	6.7	84	56	150	86.2
7.1 Preferred DR-TB treatment regimen to use at this facility (n=150)																				
Standard long regimen for RR/MDR-TB with Bedaquiline (WHO)	2	50	3	15.8	24	21.6	1	33.3	5	38.5	--	--	15	26.8	3	30	17	20.2	35	23.3
Standard long regimen for RR/MDR-TB without Bedaquiline (WHO)	0	0	2	10.5	4	3.6	0	0	0	0	--	--	3	5.4	0	0	3	3.6	6	4
Standard shorter regimen with injectable for RR/MDR-TB (WHO)	1	25	0	0	2	1.8	0	0	0	0	--	--	0	0	0	0	3	3.6	3	2

Standard all oral shorter regimen for RR/MDR-TB: 9 months regimen with Pto (WHO)	0	0	8	42.1	33	29.7	1	33.3	7	53.8	--	--	23	41.1	3	30	23	27.4	49	32.7
Standard all oral shorter regimen for RR/MDR-TB: 9 months regimen with Lzd (WHO)	0	0	2	10.5	6	5.4	1	33.3	0	0	--	--	1	1.8	0	0	8	9.5	9	6
Individualized long regimen	0	0	0	0	3	2.7	0	0	0	0	--	--	0	0	0	0	3	3.6	3	2
DR-TB Treatment Regimens are available at the health facility (n=150)																				
7.2.1 Standard long regimen for RR/ MDR-TB with Bedaquiline (WHO)	2	50	8	42.1	45	40.5	2	66.7	12	92.3	--	--	37	66.1	6	60	26	31	69	46
7.2.2 Standard long regimen for RR/ MDR-TB without Bedaquiline (WHO)	0	0	5	26.3	20	18	0	0	10	76.9	--	--	22	39.3	5	50	8	9.5	35	23.3
7.2.3 Standard shorter regimen with injectable for RR/MDR-TB (WHO)	1	25	0	0	13	11.7	0	0	3	23.1	--	--	11	19.6	0	0	6	7.1	17	11.3
7.2.4 Standard all oral shorter regimen for RR/MDR TB: 9 months regimen with Pto	0	0	9	47.4	50	45	2	66.7	12	92.3	--	--	35	62.5	5	50	33	39.3	73	48.7
7.2.5 Standard all oral shorter regimen for RR/MDR TB: 9 months regimen with Lzd	0	0	4	21.1	32	28.8	2	66.7	7	53.8	--	--	23	41.1	3	30	19	22.6	45	30
7.2.6 Individualized long regimen	1	25	0	0	14	12.6	1	33.3	11	84.6	--	--	19	33.9	1	10	7	8.3	27	18
7.2.7 Short regimen without injectable for RR/MDR-TB patients who are resistant	0	0	1	5.3	10	9	1	33.3	7	53.8	--	--	15	26.8	1	10	3	3.6	19	12.7
7.2.8 Standard all oral shorter regimen for RR/MDR (BPaLM): 6 months	0	0	0	0	0	0	0	0	0	0	--	--	0	0	0	0	0	0	0	0
Total	4	100	19	100	111	100	3	100	13	100	--	--	56	100	10	100	84	100	150	100

2.1.4 Pediatric Services

Table 2.1.4a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.2.1 Facility provides TB diagnosis services to children (under 5 years of age) (n=165)	2	25	5	33.3	68	54.4	3	100	12	92.3	1	100	37	61.7	6	46.2	48	52.2	91	55.2
2.5.2 Facility provides TB treatment services to children (n=174)	3	37.5	9	39.1	110	87.3	3	100	11	84.6	0	0	51	82.3	10	76.9	75	75.8	136	78.2
Ways children are evaluated for TB disease (n=91)																				
8.1.1 Identify children with presumptive TB by symptoms	2	100	5	100	66	97.1	3	100	12	100	1	100	37	100	5	83.3	47	97.9	89	97.8
8.1.2 Once identified, all children with presumptive TB are evaluated at this facility	1	50	5	100	65	95.5	2	66.7	12	100	1	100	34	91.9	5	83.3	47	98	86	94.5
8.1.3 Once identified, all children with presumptive TB are referred for evaluation	1	50	4	80	62	91.1	1	33.3	10	83.3	0	0	29	78.3	5	83.3	44	91.7	78	85.7
Ways children with presumptive TB are evaluated (n=86)																				
8.2.1 Use clinical algorithms to determine if a child has TB	0	0	5	100	43	66.1	2	100	11	91.7	1	100	24	70.6	2	40	36	76.6	62	72.1
8.2.2 By X-ray	1	100	4	80	62	95.4	2	100	12	100	1	100	32	94.1	5	100	45	95.7	82	95.4
8.2.3 Use sputum induction to get samples for testing	1	100	5	100	49	75.3	2	100	12	100	1	100	30	88.2	2	40	38	80.9	70	81.4
8.2.4 Test sputum with smear microscopy	1	100	2	40	20	30.8	1	50	10	83.3	0	0	20	58.8	2	40	12	25.6	34	39.5
8.2.5 Test sputum with culture	1	100	2	40	20	30.8	1	50	10	83.3	0	0	20	58.8	2	40	12	25.6	34	39.5
8.2.6 Test sputum with Xpert	1	100	4	80	29	44.6	2	100	12	100	0	0	24	70.6	3	60	21	44.7	48	55.8

8.2.7 Use gastric aspiration to get samples for testing	1	100	2	40	22	33.9	2	100	9	75	0	0	17	50	3	60	16	34	36	41.9
8.2.8 Test gastric aspirate sample with Xpert	1	100	2	40	23	35.4	2	100	8	66.7	0	0	18	52.9	4	80	14	29.8	36	41.8
8.2.11 Test stool samples with Xpert	1	100	3	60	26	40	2	100	10	83.3	0	0	21	61.8	3	60	18	38.2	42	48.9
8.2.12 Test urine with LAM	0	0	2	40	16	24.6	1	50	1	8.3	0	0	9	26.5	1	20	10	21.2	20	23.3
8.2.13 Test cerebrospinal fluid (CSF)	0	0	2	40	18	27.7	2	100	7	58.4	1	100	18	52.9	1	20	11	23.4	30	34.9
8.2.14 Test lymph node aspirate	0	0	2	40	18	27.7	2	100	7	58.3	1	100	18	52.9	1	20	11	23.4	30	34.9

Table 2.1.4b

TB Treatment Medications for Children	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
8.4.1 Facility uses fixed-dose combinations (FDCs)	2	66.7	3	33.3	77	70	2	66.7	9	81.8	--	--	33	64.7	7	70	53	70.7	93	68.4
8.4.2 Facility uses loose or single-drug formulations (for treating TB disease, not TPT regimen)	2	66.7	2	22.2	62	56.4	2	66.7	9	81.8	--	--	36	70.6	7	70	34	45.3	77	56.6
8.4.3 Facility uses the shorter 4-month treatment regimen for DS-TB for eligible children	0	0	0	0	5	4.5	0	0	0	0	--	--	0	0	0	0	5	6.7	5	3.7
8.4.4 Facility uses the same medications used for adults but cut up for children	0	0	0	0	0	0	0	0	0	0	--	--	0	0	0	0	0	0	0	0
Total	3	100	9	100	110	100	3	100	11	100	--	--	51	100	10	100	75	100	136	100

2.1.5 LTBI Services

Table 2.1.5a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
20V.1.1 Facility provides any type of screening for LTBI (n=180)	3	37.5	13	46.4	102	80.3	2	66.7	11	84.6	0	0	50	78.1	12	85.7	69	67.6	131	72.8
20V.2.1 Facility provides any type of diagnosis services for LTBI (n=180)	2	25	10	35.7	100	78.7	2	66.7	11	84.6	1	100	50	78.1	10	71.4	66	64.7	126	70
20V.4.1 Facility has provided any form of treatment for LTBI (n=180)	2	25	8	28.6	95	74.8	1	33.3	7	53.8	1	100	44	68.8	11	78.6	59	57.8	114	63.3
Types of screening for LTBI conducted (n=131)																				
20V.1.2 Screening for LTBI by TB skin test (TST)	3	100	10	76.9	96	94.1	2	100	11	100	--	--	49	98	12	100	61	88.4	122	93.1
20V.1.3 Screening for LTBI by blood tests	0	0	0	0	6	5.9	0	0	2	18.2		--	3	6	1	8.3	4	5.8	8	6.1
20V.1.4 Participants charged a fee for LTBI screening tests	0	0	0	0	7	6.9	0	0	2	18.2		--	6	12	0	0	3	4.3	9	6.9
Total	3	100	13	100	102	100	2	100	11	100	--	--	50	100	12	100	69	100	131	100
LTBI Diagnosis Services offered (n=126)																				
20V.2.2 Diagnosis of LTBI by historical contacts with high-risk groups	2	100	8	80	99	99	2	100	11	100	1	100	48	96	10	100	65	98.5	123	97.6
20V.2.3 Diagnosis of LTBI by active case finding	2	100	8	80	78	78	2	100	10	90.9	0	0	39	78	9	90	52	78.8	100	79.4

20V.2.4 Diagnosis of LTBI by community-based screening	2	100	7	70	76	76	2	100	11	100	0	0	40	80	9	90	49	74.2	98	77.8
20V.2.5 Diagnosis of LTBI by physical examination	1	50	6	60	75	75	2	100	8	72.7	1	100	39	78	7	70	47	71.2	93	73.8
20V.2.6 Diagnosis of LTBI by TB skin test (TST)	2	100	8	80	93	93	2	100	11	100	0	0	48	96	10	100	58	87.9	116	92.1
20V.2.7 Diagnosis of LTBI by blood tests (IGRAs)	0	0	0	0	4	4	0	0	2	18.2	1	100	4	2	20	1	1.5	7	5.6	
20V.2.8 Participants charged a fee for LTBI diagnosis tests	0	0	0	0	4	4	0	0	2	18.2	0	0	5	10	0	0	1	1.5	6	4.8
Total	2	100	10	100	100	100	2	100	11	100	1	100	50	100	10	100	66	100	126	100
LTBI Treatment Services Offered (n=114)																				
20V.4.2 Treatment of LTBI with isoniazid and rifapentine (3HP)	1	50	2	25	52	54.7	0	0	6	85.7	1	100	25	56.8	8	72.7	29	49.2	62	54.4
20V.4.3 Facility asks patients about any LTBI drug side-effects they experienced	2	100	7	87.5	90	94.7	1	100	7	100	1	100	41	93.2	11	100	56	94.9	108	94.7
20V.4.5 Facility captures all reported side-effects in the LTBI register	1	50	5	62.5	70	73.7	1	100	6	85.7	1	100	33	75	8	72.7	43	72.9	84	73.7
20V.4.6 Facility provides LTBI patients with any ancillary drugs to manage the side effects	0	0	1	12.5	43	45.3	1	100	5	71.4	0	0	22	50	2	18.2	26	44.1	50	43.9
Total	2	100	8	100	95	100	1	100	7	100	1	100	44	100	11	100	59	100	114	100

2.1.6. Contact Investigation Services

Table 2.1.6a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
4.1 Contact investigation and management according to TB program guidelines conducted at facility (n=180)	3	37.5	21	75	117	92.1	2	66.7	11	84.6	0	0	55	85.9	12	85.7	87	85.3	154	85.6
Contact investigations conducted for: (n=154)																				
4.1.1 Adult contacts	3	100	21	100	113	96.6	2	100	10	90.9	--	--	53	96.4	12	100	84	96.6	149	96.8
4.1.2 Child contacts (under 5 years old)	3	100	19	90.5	107	91.5	2	100	11	100	--	--	53	96.4	11	91.7	78	89.7	142	92.2
Both adult and child contacts	3	100	19	90.5	106	90.6	2	100	10	90.9	--	--	51	92.7	11	91.7	78	89.7	140	90.9

2.1.7. TB-HIV Linkages

Table 2.1.7a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.3 Facility provides HIV-related services (n=180)	8	100	27	96.4	126	99.2	3	100	13	100	1	100	64	100	13	92.9	101	99	178	98.9
Types of HIV-related services provided by health facilities																				
5.1 HIV testing and counseling for presumptive TB patients (n=178)	1	12.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0.6
5.2 HIV testing and counseling for confirmed TB patients (n=178)	6	75	14	51.9	123	97.6	3	100	13	100	1	100	61	95.3	13	100	86	85.1	160	89.9
5.3 Recency testing for HIV (n=163)	7	100	13	86.7	116	93.5	3	100	13	100	1	100	60	98.4	11	84.6	82	92.1	153	93.9
5.5 TB preventive therapy (TPT) (n=178)	5	62.5	13	48.1	99	78.6	3	100	10	76.9	1	100	51	79.7	8	61.5	72	71.3	131	73.6
5.5.7 TPT available through a differentiated service delivery model (n=178)	0	0	1	3.7	9	7.1	0	0	2	15.4	0	0	5	7.8	1	7.7	6	5.9	12	6.7
5.9 HIV care and treatment services provided to TB/HIV co-infected patients (n=178)	6	75	2	7.4	66	52.4	2	66.7	6	46.2	1	100	38	59.4	3	23.1	42	41.6	83	46.6
5.9.1 Co-trimoxazole (CPT) for TB/HIV co-infected patients (n=83)	4	66.7	2	100	45	68.2	1	50	6	100	1	100	33	86.8	1	33.3	25	59.5	59	71.1
5.9.2 Viral load testing for TB/HIV co-infected patients (n=83)	2	33.3	0	0	25	37.9	1	50	1	16.7	1	100	15	39.5	1	33.3	14	33.3	30	36.1

5.9.3 ART for TB/HIV co-infected patients (n=83)	5	83.3	2	100	51	77.3	1	50	3	50	1	100	31	81.6	1	33.3	31	73.8	63	75.9
5.4 (a) Facility has referred patients elsewhere for HIV testing and counselling in the past 6 months (n=100)	1	20	2	10.5	15	22.1	0	0	4	66.7	--	--	7	20.6	1	12.5	14	24.1	22	22
5.5.8 (a) Facility has referred HIV patients elsewhere for TPT in the past 6 months (n=47)	1	33.3	1	7.1	12	44.4	--	--	3	100	--	--	6	46.2	4	80	7	24.1	17	36.2

2.1.8. CHW services

Table 2.1.8a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.6 Facility uses community-based health workers (CHWs) or volunteers for TB services (n=180)	1	12.5	14	50	58	45.7	0	0	5	38.5	0	0	24	37.5	5	35.7	49	48	78	43.3
TB services provided by community-based workers or volunteers																				
9.1.1 Education about TB control and prevention in the community (n=78)	1	100	14	100	56	96.6	--	--	5	100	--	--	23	95.8	5	100	48	98	76	97.4
9.1.2 Screening for TB symptoms (n=78)	1	100	11	78.6	43	74.1	--	--	4	80	--	--	17	70.8	3	60	39	79.6	59	75.6
9.1.3 Referral for TB diagnosis for presumptive TB patients (n=78)	1	100	14	100	55	94.8	--	--	5	100	--	--	22	91.7	5	100	48	98	75	96.2

9.1.4 Collection and transportation of specimens to a diagnostic laboratory (n=4)	1	25	--	--	--	--	--	--	--	--	--	--	1	100	--	--	0	0	1	25
9.1.5 Direct observation of treatment (DOT) (n=66)	--	--	3	37.5	44	78.6	--	--	2	100	--	--	13	72.2	4	100	32	72.7	49	74.2
9.1.6 Adherence counseling (n=78)	1	100	12	85.7	56	96.6	--	--	5	100	--	--	23	95.8	4	80	47	95.9	74	94.9
9.1.7 Trace or locate clients who miss follow-up visits (n=78)	1	100	12	85.7	56	96.6	--	--	5	100	--	--	24	100	5	100	45	91.8	74	94.9
9.1.8 Contact tracing for confirmed TB patients (n=78)	1	100	13	92.9	57	98.3	--	--	5	100	--	--	24	100	5	100	47	95.9	76	97.4
9.1.9 Psychosocial support for TB patients and their families (n=78)	1	100	11	78.6	52	89.7	--	--	4	80	--	--	21	87.5	5	100	42	85.7	68	87.2
9.1.10 HIV testing and counseling for TB patients (n=78)	1	100	6	42.9	43	74.1	--	--	4	80	--	--	16	66.7	4	80	34	69.4	54	69.2

2.1.9. CHW management

Table 2.1.9a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
9.3.1 CHWs associated with this facility receive training in TB (n=78)	1	100	11	78.6	47	81	--	--	3	60	--	--	16	66.7	4	80	42	85.7	62	79.5
9.3.2 Facility has an up-to-date list of CHWs who provide DOT (n=49)	--	--	2	66.7	34	77.3	--	--	2	100	--	--	8	61.5	3	75	27	84.4	38	77.6

9.3.3 Facility keeps a record of the performance of the CHWs (n=78)	0	0	5	35.7	23	39.7	--	--	1	20	--	--	4	16.7	1	20	24	49	29	37.2
9.3.4 Facility TB focal person meets regularly with CHWs (n=78)	1	100	11	78.6	51	87.9	--	--	3	60	--	--	20	83.3	5	100	41	83.7	66	84.6
9.3.5 Facility staff conduct community-level supervision of the CHWs (n=78)	1	100	7	50	44	75.9	--	--	3	60	--	--	14	58.3	5	100	36	73.5	55	70.5

2.2. Laboratory Infrastructure

2.2.1. Specimen Management and Transport (onsite laboratories)

Table 2.2.1a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.2.3 Facility collects a sputum sample from new presumptive TB clients (n=165)	6	75	14	93.3	123	98.4	3	100	13	100	1	100	60	100	13	100	87	94.6	160	97
15.1.1 Facility correctly identified when sputum should be collected from patients (n=180)	8	100	24	85.7	120	94.5	3	100	11	84.6	1	100	59	92.2	13	92.9	95	93.1	167	92.8
15.1.2 Facility has SOPs for specimen collection (observed) (n=180)	6	75	19	67.9	105	82.7	3	100	11	84.6	1	100	54	84.4	11	78.6	80	78.4	145	80.6
15.1.3 Facility has approved laboratory request forms (observed) (n=180)	5	62.5	18	64.3	107	84.3	3	100	12	92.3	1	100	50	78.1	12	85.7	84	82.4	146	81.1

15.1.4 Facility experienced any stockouts of specimen management supplies in the past 6 months (n=180)	3	37.5	5	17.9	18	14.2	0	0	3	23.1	0	0	14	21.9	0	0	15	14.7	29	16.1
15.2.1 Facility maintains any sputum containers that are sealable and leakproof (n=180)	6	100	12	85.7	115	92.7	3	100	12	92.3	1	100	53	89.8	13	100	83	93.3	149	92.5

Table 2.2.1b

		Facility Type						Facility Location			Total
		District General Hospital	District Preventive Health Center (one function)	District Health Center (two-function)	CDC	Lung Hospital	Provincial General Hospital	Urban	Peri-urban	Rural	
Turnaround time for specimens to arrive at onsite laboratory (hours)	Median	1.0 hours	1.0 hours	1.0 hours	1.0 hours	1.0 hours	1 hour	1.0 hours	1.5 hours	1.0 hours	1.0 hours
	Range	[1 - 2 hours]	[1 - 4 hours]	[1 - 48 hours]	[1 hour]	[1 - 24 hours]	[1 hour]	[1 - 48 hours]	[1 - 30]	[1 - 48 hours]	[1 - 48 hours]
	Total Facilities	5	13	103	3	13	1	52	10	76	138
Turnaround time for test results to be received by provider from the onsite laboratory (hours)	Median	2.0 hours	2.0 hours	3.0 hours	1.0 hours	4.0 hours	1 hour	2.0 hours	5.0 hours	2.0 hours	2.0 hours
	Range	[1 - 7 hours]	[1 - 4 hours]	[1 - 48 hours]	[1 - 2 hours]	[1 - 24 hours]	[1 hour]	[1 - 48 hours]	[1 - 24]	[1 - 24]	[1 - 48 hours]
	Total Facilities	6	14	115	3	13	1	57	10	85	152

2.2.2. Offsite Laboratories

Table 2.2.2a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
2.2.4 Facility collects sputum samples from persons presumed to have TB (n=15)	–	–	3	23.1	1	50.0	0	0	0	0	0	0	1	25.0	0	0	3	30.0	4	26.7
TB Diagnostic Tests Performed by offsite laboratories (n=4)																				
15.3.1.1 Smear microscopy	--	--	0	0	1	100	--	--	--	--	--	--	0	0	--	--	1	33.3	1	25
15.3.1.2 Xpert MTB/RIF	--	--	2	66.7	1	100	--	--	--	--	--	--	1	100	--	--	2	66.7	3	75
15.3.1.3 Xpert Ultra	--	--	2	66.7	1	100	--	--	--	--	--	--	1	100	--	--	2	66.7	3	75
15.3.1.4 Xpert MTB/XDR	--	--	2	66.7	1	100	--	--	--	--	--	--	1	100	--	--	2	66.7	3	75
15.3.1.5 First-line drug susceptibility testing (other than Xpert)	--	--	2	66.7	1	100	--	--	--	--	--	--	1	100	--	--	2	66.7	3	75
15.3.1.6 Second-line drug susceptibility testing	--	--	2	66.7	1	100	--	--	--	--	--	--	1	100	--	--	2	66.7	3	75
15.3.3 Up-to-date specimen referral register observed	--	--	2	66.7	1	100	--	--	--	--	--	--	1	100	--	--	2	66.7	3	75
15.3.5 Facility has access to a specimen transport service	--	--	2	66.7	0	0	--	--	--	--	--	--	1	100	--	--	1	33.3	2	50
15.3.6 Facility uses a cooler box reserved for transportation of specimens	--	--	3	100	1	100	--	--	--	--	--	--	1	100	--	--	3	100	4	100
Total	--	--	3	100	1	100	--	--	--	--	--	--	1	100	--	--	3	100	4	100

Table 2.2.2b

Turnaround Times (offsite laboratories)		Facility Type						Facility Location			Total
		District General Hospital	District Preventive Health Center (one function)	District Health Center (two-function)	CDC	Lung Hospital	Provincial General Hospital	Urban	Peri-urban	Rural	
Turnaround time for specimens to arrive at offsite laboratory (days)	Median	--	2.0 days	<1 days	--	--	--	2.0 days	--	1.0 days	1.0 days
	Range	--	[1 days]	[<1 days]	--	--	--	[2 days]	--	[1 - 3 days]	[1 - 3 days]
	Total Facilities	--	3	1	--	--	--	1	--	3	4
Turnaround time for test results to be received by provider from the onsite laboratory (days)	Median	--	1.7 days	< 1 day	--	--	--	2 days	--	<1 day	1.0 days
	Range	--	[< 1 day - 3 days]	[< 1 day]	--	--	--	[2 days]	--	[<1 day - 3 days]	[<1 day - 3 days]
	Total Facilities	--	3	1	--	--	--	1	--	3	4

2.2.3. Quality Assurance

Table 2.2.3a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
14.8 Type of quality control and quality assurance (QC/QA) do you use by facilities with onsite lab (n=161)																				
None	1	16.7	4	28.6	8	6.5	0	0	0	0	0	3	5.1	15.4	8	0	13	8.1		
Internal QC/QA only	1	16.7	6	42.9	38	30.6	0	0	0	0	1	15	25.4	30.8	27	30.3	100	46	28.6	
External QC/QA only	1	16.7	3	21.4	20	16.1	1	33.3	0	0	0	9	15.3	2	15.4	14	15.7	0	25	15.5
Both internal and external QC/QA	2	33.3	1	7.1	57	46	2	66.7	13	100	0	31	52.5	5	38.5	39	43.8	0	75	46.6
Don't know	1	16.7	0	0	1	0.8	0	0	0	0	0	1	1.7	0	1	1.1	0	2	1.2	
Total	6	100	14	100	124	100	3	100	13	100	1	59	100	13	100	89	100	100	161	100
14.8.1 Facility maintains records of the results from the QC/QA procedures (n=146)	3	75	8	80	105	91.3	3	100	13	100	0	50	90.9	10	90.9	72	90	0	132	90.4
14.8.2a Facility has guidelines and procedures for QC/QA (either internal or external) (n=146)	3	75	8	80	95	82.6	3	100	13	100	0	49	89.1	6	54.5	67	83.8	0	122	83.6

2.3. Medical Equipment and Drug Availability

2.3.1. Basic TB Care equipment Availability

Table 2.3.1a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Other		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Functional DS-TB equipment observed at facility (n=180)																				
13.1 Adult Scale	8	100	27	96.4	127	100	3	103	100	1	100	64	100	14	100	101	99	179	99.4	
13.3 Infant Scale	5	62.5	7	25	87	68.5	2	66.7	1	7.7	1	100	28	43.8	6	42.9	69	67.6	103	57.2
13.5 Thermometer	8	100	27	96.4	126	99.2	3	100	13	100	1	100	63	98.4	14	100	101	99	178	98.9
13.6 Stethoscope	8	100	27	96.4	127	100	3	103	100	1	100	64	100	14	100	101	99	179	99.4	
13.7 Blood Pressures Cuff	8	100	27	96.4	127	100	3	103	100	1	100	64	100	14	100	101	99	179	99.4	
13.8 Light Source	7	87.5	21	75	127	100	3	100	12	92.3	1	100	61	95.3	14	100	96	94.1	171	95
13.9 IV Kits	7	87.5	21	75	116	91.3	2	66.7	13	100	1	100	53	82.8	11	78.6	96	94.1	160	88.9
13.10 Oxygen Concentrator	8	100	8	28.6	94	74	2	66.7	12	92.3	1	100	46	71.9	9	64.3	70	68.6	125	69.4
13.11 Oxygen Cylinders	8	100	17	60.7	123	96.9	3	100	13	100	1	100	58	90.6	14	100	93	91.2	165	91.7
13.12 Central Oxygen Supply	8	100	0	0	76	59.8	0	0	13	100	1	100	35	54.7	5	35.7	58	56.9	98	54.4
13.13 Flowmeter	8	100	16	57.1	120	94.5	3	100	13	100	1	100	56	87.5	13	92.9	92	90.2	161	89.4
13.14 Oxygen Delivery Apparatus	8	100	18	64.3	117	92.1	3	100	13	100	1	100	56	87.5	12	85.7	92	90.2	160	88.9
Functional DR-TB equipment observed at facility (n=156)																				
7.13.1 ECG Machine	4	100	6	25	99	88.4	3	100	12	92.3	--	--	49	84.5	8	72.7	67	77	124	79.5
7.13.2 Audiology Machine	0	0	0	0	4	3.6	2	66.7	9	69.2	--	--	11	19	0	0	4	4.6	15	9.6

2.3.2. Laboratory Equipment Availability (for facilities with onsite lab)

Table 2.3.2a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Functional lab equipment available at facility (n=161)																				
14.2 Light Microscope	6	100	13	92.9	112	90.3	3	100	12	92.3	1	100	51	86.4	12	92.3	84	94.4	147	91.3
14.1.1 Carbol Fuchsin	4	66.7	9	64.3	98	79	2	66.7	13	100	1	100	50	84.7	9	69.2	68	76.4	127	78.9
14.1.2 Sulphuric Acid	5	83.3	12	85.7	100	80.6	3	100	12	92.3	0	0	51	86.4	9	69.2	72	80.9	132	82
14.1.3 Methyl Blue	6	100	14	100	117	94.4	3	100	13	100	1	100	57	96.6	10	76.9	87	97.8	154	95.7
14.3 Fluorescence Microscope	1	16.7	1	7.7	13	10.5	0	0	8	61.5	0	0	15	25.4	0	0	8	9.1	23	14.4
14.3.1 Auramine Stain	0	0	0	0	0	0	0	6	46.2	0	0	6	10.2	0	0	0	0	6	3.8	
Total	6	100	14	100	124	100	3	100	13	100	1	100	59	100	13	100	89	100	161	100

Table 2.3.2b

Table 2.15.2b

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
GeneXpert Cartridges used by and available at the health facility																				
14.5.1(a)(a) 6 color cartridge used at facility (n=33)	0	0	2	100	6	42.9	3	100	12	92.3	--	--	18	75	0	0	5	62.5	23	69.7
14.5.1(a)(b) 6 color cartridge available (n=23)	--	--	2	100	6	100	3	100	12	100	--	--	18	100	--	--	5	100	23	100
14.5.1(b)(a) 10 color cartridge used at facility (n=33)	0	0	0	0	1	7.1	0	0	4	30.8	--	--	5	20.8	0	0	0	0	5	15.2
14.5.1(b)(b) 10 color cartridge available (n=5)	--	--	--	--	1	100	--	--	4	100	--	--	5	100	--	--	--	--	5	100

14.5.2(a) Xpert MTB/RIF cartridge used at facility (n=27)	1	100	2	100	9	90	3	100	11	100	--	--	18	94.7	1	100	7	100	26	96.3
14.5.2(b) Xpert MTB/RIF cartridge available (n=26)	1	100	2	100	9	100	3	100	11	100	--	--	18	100	1	100	7	100	26	100
14.5.3(a) Xpert Ultra cartridge used at facility (n=29)	1	100	1	100	12	100	3	100	12	100	--	--	21	100	1	100	7	100	29	100
14.5.3.(b) Xpert Ultra Cartridge available (n=29)	1	100	1	100	12	100	3	100	12	100	--	--	21	100	1	100	7	100	29	100
14.5.4(a) Xpert MTB/XDR cartridge used at facility (n=1)	--	--	--	--	--	--	--	--	1	100	--	--	1	100	--	--	--	--	1	100
14.5.4.(b) Xpert MTB/XDR Cartridge available (n=1)	--	--	--	--	--	--	--	--	1	100	--	--	1	100	--	--	--	--	1	100

2.3.3. Drug Availability

Drug Availability at DS-TB treatment facilities

Table 2.3.3a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
17.1.1 Isoniazid																				
Never stocked	0	0	5	21.7	15	11.9	0	0	0	0	0	0	2	3.2	0	0	18	18.2	20	11.5
No stock observed	1	12.5	6	26.1	14	11.1	0	0	0	0	0	4	6.5	1	7.7	16	16.2	21	12.1	
Stocked but distributed	0	0	1	4.3	8	6.3	0	0	0	0	0	0	1	1.6	0	0	8	8.1	9	5.2
Observed, at least one valid	7	87.5	11	47.8	88	69.8	3	100	13	100	1	100	55	88.7	12	92.3	56	56.6	123	70.7
Don't Know	0	0	0	0	1	0.8	0	0	0	0	0	0	0	0	0	0	1	1	1	0.6
17.1.2 Rifampicin																				
Never stocked	0	0	10	43.5	27	21.4	0	0	1	7.7	0	0	4	6.5	0	0	34	34.3	38	21.8
No stock observed	2	25	9	39.1	27	21.4	1	33.3	3	23.1	0	12	19.4	0	0	30	30.3	42	24.1	
Stocked but distributed	0	0	0	0	10	7.9	0	0	0	0	0	0	3	4.8	0	0	7	7.1	10	5.7
Observed, at least one valid	6	75	4	17.4	61	48.4	2	66.7	9	69.2	1	100	43	69.4	13	100	27	27.3	83	47.7
Don't Know	0	0	0	0	1	0.8	0	0	0	0	0	0	0	0	0	0	1	1	1	0.6
17.1.3 Pyrazinamide																				
Never stocked	0	0	8	34.8	13	10.3	0	0	0	0	0	0	2	3.2	0	0	19	19.2	21	12.1
No stock observed	1	12.5	6	26.1	13	10.3	0	0	0	0	0	3	4.8	0	0	17	17.2	20	11.5	
Stocked but distributed	0	0	2	8.7	13	10.3	0	0	0	0	0	0	4	6.5	0	0	11	11.1	15	8.6
Observed, at least one valid	7	87.5	7	30.4	87	69	3	100	13	100	1	100	53	85.5	13	100	52	52.5	118	67.8
17.1.4 Ethambutol																				
No stock observed	0	0	7	30.4	2	1.6	0	0	0	0	1	100	3	4.8	0	0	7	7.1	10	5.7
Stocked but distributed	0	0	3	13	1	0.8	0	0	0	0	0	0	1	1.6	0	0	3	3	4	2.3
Observed, at least one valid	8	100	13	56.5	123	97.6	3	100	13	100	0	0	58	93.5	13	100	89	89.9	160	92
17.1.5 Isoniazid + rifampicin (2FDC)																				
Never stocked	2	25	3	13	10	7.9	0	0	0	0	0	6	9.7	1	7.7	8	8.1	15	8.6	
No stock observed	0	0	5	21.7	1.6	1	33.3	1	7.7	0	0	6	9.7	0	0	3	9	5.2		

Stocked but distributed	0	0	0	0	2	1.6	0	0	0	0	0	0	0	0	0	0	2	2	2	1.1
Observed, at least one valid	6	75	15	65.2	112	88.9	2	66.7	12	92.3	1	100	50	80.6	12	92.3	86	86.9	148	85.1
17.1.6 Isoniazid + ethambutol (EH) (2FDC)																				
Never stocked	7	87.5	19	82.6	113	89.7	3	100	10	76.9	1	100	53	85.5	11	84.6	89	89.9	153	87.9
No stock observed	1	12.5	4	17.4	4	3.2	0	0	0	0	0	0	3	4.8	1	7.7	5	5.1	9	5.2
Stocked but distributed	0	0	0	0	1	0.8	0	0	1	7.7	0	0	1	1.6	0	0	1	1	2	1.1
Observed, at least one valid	0	0	0	0	6	4.8	0	0	2	15.4	0	0	4	6.5	0	0	4	4	8	4.6
Don't Know	0	0	0	0	2	1.6	0	0	0	0	0	0	1	1.6	1	7.7	0	0	2	1.1
17.1.7 Isoniazid + rifampicin + pyrazinamide (RHZ) (3FDC)																				
Never stocked	1	12.5	4	17.4	8	6.3	0	0	0	0	0	0	5	8.1	0	0	8	8.1	13	7.5
No stock observed	0	0	6	26.1	3	2.4	0	0	0	0	0	0	4	6.5	0	0	5	5.1	9	5.2
Stocked but distributed	1	12.5	1	4.3	1	0.8	0	0	0	0	0	0	0	0	0	0	3	3	3	1.7
Observed, at least one valid	6	75	12	52.2	114	90.5	3	100	13	100	1	100	53	85.5	13	100	83	83.8	149	85.6
17.1.8 Isoniazid + rifampicin + ethambutol (RHE) (3FDC)																				
Never stocked	7	87.5	18	78.3	111	88.1	3	100	10	76.9	1	100	51	82.3	9	69.2	90	90.9	150	86.2
No stock observed	1	12.5	5	21.7	7	5.6	0	0	0	0	0	0	4	6.5	1	7.7	8	8.1	13	7.5
Stocked but distributed	0	0	0	0	1	0.8	0	0	1	7.7	0	0	2	3.2	0	0	0	0	2	1.1
Observed, at least one valid	0	0	0	0	4	3.2	0	0	2	15.4	0	0	4	6.5	1	7.7	1	1	6	3.4
Don't Know	0	0	0	0	3	2.4	0	0	0	0	0	0	1	1.6	2	15.4	0	0	3	1.7
17.1.9 Isoniazid + rifampicin + pyrazinamide + ethambutol (4FDC)																				
Never stocked	7	87.5	19	82.6	112	88.9	3	100	9	69.2	1	100	52	83.9	10	76.9	89	89.9	151	86.8
No stock observed	1	12.5	4	17.4	11	8.7	0	0	2	15.4	0	0	6	9.7	2	15.4	10	10.1	18	10.3
Stocked but distributed	0	0	0	0	1	0.8	0	0	1	7.7	0	0	2	3.2	0	0	0	0	2	1.1
Observed, at least one valid	0	0	0	0	0	0	0	0	1	7.7	0	0	1	1.6	0	0	0	0	1	0.6
Don't Know	0	0	0	0	2	1.6	0	0	0	0	0	0	1	1.6	1	7.7	0	0	2	1.1
17.1.10 Streptomycin injectable																				
Never stocked	2	25	7	30.4	39	31	2	66.7	3	23.1	0	0	18	29	5	38.5	30	30.3	53	30.5
No stock observed	1	12.5	13	56.5	49	38.9	1	33.3	2	15.4	0	0	17	27.4	2	15.4	47	47.5	66	37.9
Stocked but distributed	0	0	2	8.7	5	4	0	0	0	0	0	0	2	3.2	0	0	5	5.1	7	4
Observed, at least one valid	5	62.5	0	0	32	25.4	0	0	8	61.5	1	100	24	38.7	5	38.5	17	17.2	46	26.4
Don't Know	0	0	1	4.3	1	0.8	0	0	0	0	0	0	1	1.6	1	7.7	0	0	2	1.1
17.1.16 Amikacin (Am)																				
Never stocked	3	37.5	15	65.2	34	27	0	0	1	7.7	1	100	17	27.4	4	30.8	33	33.3	54	31

No stock observed	5	62.5	6	26.1	55	43.7	3	100	6	46.2	0	0	28	45.2	3	23.1	44	44.4	75	43.1
Stocked but distributed	0	0	2	8.7	25	19.8	0	0	2	15.4	0	0	14	22.6	5	38.5	10	10.1	29	16.7
Observed, none valid	0	0	0	0	1	0.8	0	0	3	23.1	0	0	2	3.2	0	0	2	2	4	2.3
Observed, at least one valid	0	0	0	0	10	7.9	0	0	1	7.7	0	0	1	1.6	0	0	10	10.1	11	6.3
Don't Know	0	0	0	0	1	0.8	0	0	0	0	0	0	0	0	1	7.7	0	0	1	0.6
17.1.17 Levofloxacin (Lfx)																				
Never stocked	1	12.5	10	43.5	14	11.1	0	0	0	0	1	100	6	9.7	1	7.7	19	19.2	26	14.9
No stock observed	2	25	3	13	22	17.5	0	0	0	0	0	0	6	9.7	0	0	21	21.2	27	15.5
Stocked but distributed	0	0	2	8.7	35	27.8	1	33.3	0	0	0	0	14	22.6	7	53.8	17	17.2	38	21.8
Observed, at least one valid	5	62.5	8	34.8	55	43.7	2	66.7	13	100	0	0	36	58.1	5	38.5	42	42.4	83	47.7
17.1.18 Moxifloxacin (Mfx)																				
Never stocked	7	87.5	20	87	76	60.3	2	66.7	5	38.5	1	100	36	58.1	2	15.4	73	73.7	111	63.8
No stock observed	0	0	3	13	19	15.1	0	0	4	30.8	0	0	10	16.1	2	15.4	14	14.1	26	14.9
Stocked but distributed	0	0	0	0	22	17.5	1	33.3	0	0	0	0	9	14.5	6	46.2	8	8.1	23	13.2
Observed, at least one valid	1	12.5	0	0	6	4.8	0	0	4	30.8	0	0	7	11.3	0	0	4	4	11	6.3
Don't Know	0	0	0	0	3	2.4	0	0	0	0	0	0	0	0	3	23.1	0	0	3	1.7
17.1.19 Prothionamide (Pto)																				
Never stocked	6	75	12	52.2	31	24.6	0	0	0	0	1	100	14	22.6	2	15.4	34	34.3	50	28.7
No stock observed	2	25	5	21.7	37	29.4	0	0	1	7.7	0	0	12	19.4	1	7.7	32	32.3	45	25.9
Stocked but distributed	0	0	1	4.3	34	27	1	33.3	0	0	0	0	13	21	9	69.2	14	14.1	36	20.7
Observed, at least one valid	0	0	5	21.7	22	17.5	2	66.7	12	92.3	0	0	23	37.1	0	0	18	18.2	41	23.6
Don't Know	0	0	0	0	2	1.6	0	0	0	0	0	0	0	0	1	7.7	1	1	2	1.1
17.1.20 Cycloserine (Cs)																				
Never stocked	6	75	12	52.2	24	19	0	0	0	0	1	100	11	17.7	2	15.4	30	30.3	43	24.7
No stock observed	1	12.5	6	26.1	27	21.4	1	33.3	0	0	0	0	11	17.7	0	0	24	24.2	35	20.1
Stocked but distributed	1	12.5	2	8.7	42	33.3	1	33.3	0	0	0	0	17	27.4	10	76.9	19	19.2	46	26.4
Observed, at least one valid	0	0	3	13	33	26.2	1	33.3	13	100	0	0	23	37.1	1	7.7	26	26.3	50	28.7
17.1.21 Para-aminosalicylic acid (PAS)																				
Never stocked	7	87.5	19	82.6	90	71.4	2	66.7	4	30.8	1	100	36	58.1	5	38.5	82	82.8	123	70.7
No stock observed	1	12.5	3	13	8	6.3	0	0	3	23.1	0	0	7	11.3	0	0	8	8.1	15	8.6
Stocked but distributed	0	0	0	0	17	13.5	1	33.3	1	7.7	0	0	9	14.5	4	30.8	6	6.1	19	10.9
Observed, at least one valid	0	0	0	0	5	4	0	0	5	38.5	0	0	8	12.9	1	7.7	1	1	10	5.7
Don't Know	0	0	1	4.3	6	4.8	0	0	0	0	0	0	2	3.2	3	23.1	2	2	7	4

17.1.22 Bedaquiline (Bdq)																				
Never stocked	5	62.5	13	56.5	32	25.4	0	0	0	0	1	100	11	17.7	3	23.1	37	37.4	51	29.3
No stock observed 2.5	3	13	17	13.5	0	0	0	0	0	0	4	6.5	0	0	17	17.2	21	12.1		
Stocked but distributed	0	0	2	8.7	43	34.1	0	0	0	0	0	0	18	29	8	61.5	19	19.2	45	25.9
Observed, at least one valid	2	25	5	21.7	34	27	3	100	13	100	0	0	29	46.8	2	15.4	26	26.3	57	32.8
17.1.23 Delamanid (Dlm)																				
Never stocked	8	100	17	73.9	80	63.5	1	33.3	6	46.2	1	100	32	51.6	4	30.8	77	77.8	113	64.9
No stock observed	0	0	3	13	12	9.5	0	0	1	7.7	0	0	6	9.7	0	0	10	10.1	16	9.2
Stocked but distributed	0	0	2	8.7	21	16.7	1	33.3	0	0	0	0	11	17.7	7	53.8	6	6.1	24	13.8
Observed, at least one valid	0	0	1	4.3	11	8.7	1	33.3	6	46.2	0	0	13	21	1	7.7	5	5.1	19	10.9
Don't Know	0	0	0	0	2	1.6	0	0	0	0	0	0	0	0	1	7.7	1	1	2	1.1
17.1.24 Linezolid (Lzd)																				
Never stocked	5	62.5	16	69.6	37	29.4	0	0	0	0	1	100	16	25.8	2	15.4	41	41.4	59	33.9
No stock observed 2.5	2	8.7	17	13.5	1	33.3	0	0	0	0	7	11.3	0	0	14	14.1	21	12.1		
Stocked but distributed	1	12.5	3	13	39	31	0	0	0	0	0	0	16	25.8	8	61.5	19	19.2	43	24.7
Observed, at least one valid	1	12.5	2	8.7	32	25.4	2	66.7	13	100	0	0	23	37.1	2	15.4	25	25.3	50	28.7
Don't Know	0	0	0	0	1	0.8	0	0	0	0	0	0	0	0	1	7.7	0	0	1	0.6
17.1.25 Clofazimine (Cfz)																				
Never stocked	4	50	12	52.2	20	15.9	0	0	0	0	1	100	9	14.5	2	15.4	26	26.3	37	21.3
No stock observed	2	25	4	17.4	20	15.9	0	0	0	0	0	0	7	11.3	0	0	19	19.2	26	14.9
Stocked but distributed 2.5	2	8.7	50	39.7	1	33.3	0	0	0	0	20	32.3	9	69.2	25	25.3	54	31		
Observed, at least one valid	1	12.5	5	21.7	36	28.6	2	66.7	13	100	0	0	26	41.9	2	15.4	29	29.3	57	32.8
Total	8	100	23	100	126	100	3	100	13	100	1	100	62	100	13	100	99	100	174	100

Table 2.3.3b Drug Availability at DR-TB treatment facilities

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
17.1.16 Amikacin (Am)																				
Never stocked	0	0	12	63.2	26	23.4	0	0	1	7.7	--	--	12	21.4	2	20	25	29.8	39	26
No stock observed	4	100	5	26.3	54	48.6	3	100	6	46.2	--	--	27	48.2	3	30	42	50	72	48
Stocked but distributed	0	0	2	10.5	21	18.9	0	0	2	15.4	--	--	14	25	4	40	7	8.3	25	16.7
Observed, none valid	0	0	0	0	1	0.9	0	0	3	23.1	--	--	2	3.6	0	0	2	2.4	4	2.7
Observed, at least one valid	0	0	0	0	8	7.2	0	0	1	7.7	--	--	1	1.8	0	0	8	9.5	9	6
Don't Know	0	0	0	0	1	0.9	0	0	0	0	--	--	0	0	1	10	0	0	1	0.7
17.1.17 Levofloxacin (Lfx)																				
Never stocked	0	0	8	42.1	10	9	0	0	0	0	--	--	3	5.4	1	10	14	16.7	18	12
No stock observed	2	50	1	5.3	19	17.1	0	0	0	0	--	--	6	10.7	0	0	16	19	22	14.7
Stocked but distributed	0	0	2	10.5	31	27.9	1	33.3	0	0	--	--	14	25	6	60	14	16.7	34	22.7
Observed, at least one valid	2	50	8	42.1	51	45.9	2	66.7	13	100	--	--	33	58.9	3	30	40	47.6	76	50.7
17.1.18 Moxifloxacin (Mfx)																				
Never stocked	4	100	17	89.5	65	58.6	2	66.7	5	38.5	--	--	31	55.4	1	10	61	72.6	93	62
No stock observed	0	0	2	10.5	18	16.2	0	0	4	30.8	--	--	10	17.9	2	20	12	14.3	24	16
Stocked but distributed	0	0	0	0	19	17.1	1	33.3	0	0	--	--	9	16.1	4	40	7	8.3	20	13.3
Observed, at least one valid	0	0	0	0	6	5.4	0	0	4	30.8	--	--	6	10.7	0	0	4	4.8	10	6.7
Don't Know	0	0	0	0	3	2.7	0	0	0	0	--	--	0	0	3	30	0	0	3	2
17.1.19 Prothionamide (Pto)																				
Never stocked	2	50	9	47.4	22	19.8	0	0	0	0	--	--	8	14.3	1	10	24	28.6	33	22
No stock observed	2	50	4	21.1	36	32.4	0	0	1	7.7	--	--	12	21.4	1	10	30	35.7	43	28.7
Stocked but distributed	0	1	5.3	29	26.1	1	33.3	0	0	--	--	13	23.2	7	70	11	13.1	31	20.7	
Observed, at least one valid	0	0	5	26.3	22	19.8	2	66.7	12	92.3	--	--	23	41.1	0	0	18	21.4	41	27.3
Don't Know	0	0	0	0	2	1.8	0	0	0	0	--	--	0	0	1	10	1	1.2	2	1.3
17.1.20 Cycloserine (Cs)																				
Never stocked	2	50	9	47.4	15	13.5	0	0	0	0	--	--	5	8.9	1	10	20	23.8	26	17.3

No stock observed	1	25	5	26.3	27	24.3	1	33.3	0	0	--	--	11	19.6	0	0	23	27.4	34	22.7
Stocked but distributed	1	25	2	10.5	37	33.3	1	33.3	0	0	--	--	17	30.4	8	80	16	19	41	27.3
Observed, at least one valid	0	0	3	15.8	32	28.8	1	33.3	13	100	--	--	23	41.1	1	10	25	29.8	49	32.7
17.1.21 Para-aminosalicylic acid (PAS)																				
Never stocked	3	75	16	84.2	77	69.4	2	66.7	4	30.8	--	--	30	53.6	3	30	69	82.1	102	68
No stock observed	1	25	2	10.5	8	7.2	0	0	3	23.1	--	--	7	12.5	0	0	7	8.3	14	9.3
Stocked but distributed	0	0	0	0	15	13.5	1	33.3	1	7.7	--	--	9	16.1	3	30	5	6	17	11.3
Observed, at least one valid	0	0	0	0	5	4.5	0	0	5	38.5	--	--	8	14.3	1	10	1	1.2	10	6.7
Don't Know	0	0	1	5.3	6	5.4	0	0	0	0	--	--	2	3.6	3	30	2	2.4	7	4.7
17.1.22 Bedaquiline (Bdq)																				
Never stocked	1	25	10	52.6	23	20.7	0	0	0	0	--	--	5	8.9	2	20	27	32.1	34	22.7
No stock observed	1	25	2	10.5	17	15.3	0	0	0	0	--	--	4	7.1	0	0	16	19	20	13.3
Stocked but distributed	0	0	2	10.5	38	34.2	0	0	0	0	--	--	18	32.1	6	60	16	19	40	26.7
Observed, at least one valid	2	50	5	26.3	33	29.7	3	100	13	100	--	--	29	51.8	2	20	25	29.8	56	37.3
17.1.23 Delamanid (Dlm)																				
Never stocked	4	100	14	73.7	69	62.2	1	33.3	6	46.2	--	--	26	46.4	3	30	65	77.4	94	62.7
No stock observed	0	0	2	10.5	11	9.9	0	0	1	7.7	--	--	6	10.7	0	0	8	9.5	14	9.3
Stocked but distributed	0	0	2	10.5	18	16.2	1	33.3	0	0	--	--	11	19.6	5	50	5	6	21	14
Observed, at least one valid	0	0	1	5.3	11	9.9	1	33.3	6	46.2	--	--	13	23.2	1	10	5	6	19	12.7
Don't Know	0	0	0	0	2	1.8	0	0	0	0	--	--	0	0	1	10	1	1.2	2	1.3
17.1.24 Linezolid (Lzd)																				
Never stocked	1	25	13	68.4	27	24.3	0	0	0	0	--	--	10	17.9	1	10	30	35.7	41	27.3
No stock observed	1	25	1	5.3	16	14.4	1	33.3	0	0	--	--	7	12.5	0	0	12	14.3	19	12.7
Stocked but distributed	1	25	3	15.8	35	31.5	0	0	0	0	--	--	16	28.6	6	60	17	20.2	39	26
Observed, at least one valid	1	25	2	10.5	32	28.8	2	66.7	13	100	--	--	23	41.1	2	20	25	29.8	50	33.3
Don't Know	0	0	0	0	1	0.9	0	0	0	0	--	--	0	0	1	10	0	0	1	0.7
17.1.25 Clofazimine (Cfz)																				
Never stocked	0	0	9	47.4	10	9	0	0	0	0	--	--	3	5.4	1	10	15	17.9	19	12.7
No stock observed	2	50	3	15.8	20	18	0	0	0	0	--	--	7	12.5	0	0	18	21.4	25	16.7
Stocked but distributed	1	25	2	10.5	46	41.4	1	33.3	0	0	--	--	20	35.7	7	70	23	27.4	50	33.3
Observed, at least one valid	1	25	5	26.3	35	31.5	2	66.7	13	100	--	--	26	46.4	2	20	28	33.3	56	37.3
Total	4	100	19	100	111	100	3	100	13	100	--	--	56	100	10	100	84	100	150	100

Table 2.3.3c

Table 2.3.3c

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
17.2 Facility maintains a buffer stock of anti-TB medication (n=180)	6	75	13	46.4	97	76.4	3	100	12	92.3	0	0	50	78.1	13	92.9	68	66.7	131	72.8
17.3 Facility experienced stockouts of anti-TB medicine in the last six months (n=180)	1	12.5	13	46.4	43	33.9	1	33.3	8	61.5	1	100	27	42.2	3	21.4	37	36.3	67	37.2
17.3.1 Any patient went without TB treatment because of stockouts within the last 6 months (n=67)	1	100	2	15.4	20	46.5	0	0	1	12.5	0	0	9	33.3	0	0	15	40.5	24	35.8

2.4. Storage Conditions

Table 2.4a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Storage conditions observed at the health facility																				
16.1 Room or store is clean and dust-free	8	100	28	100	123	96.9	3	100	13	100	1	100	62	96.9	14	100	100	98	176	97.8
16.2 Supplies and commodities (including drugs) are stored to prevent water damage	8	100	28	100	126	99.2	3	100	13	100	1	100	63	98.4	14	100	102	100	179	99.4
16.3 Room or store is adequately ventilated	8	100	27	96.4	118	92.9	3	100	11	84.6	1	100	59	92.2	14	100	95	93.1	168	93.3
16.4 Room or store is properly lit	7	87.5	28	100	126	99.2	3	100	13	100	1	100	62	96.9	14	100	102	100	178	98.9
16.5 Supplies and commodities (including drugs) are stored away from direct sunlight	8	100	27	96.4	127	100	3	100	13	100	1	100	64	100	14	100	101	99	179	99.4
16.6 Room or store has proper temperature	8	100	24	85.7	118	92.9	3	100	13	100	1	100	58	90.6	14	100	95	93.1	167	92.8
16.7 Supplies and commodities (including drugs) are stored without direct contact to floor and walls	7	87.5	24	85.7	123	96.9	3	100	13	100	0	0	59	92.2	14	100	97	95.1	170	94.4
Total	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100

2.5. Infection Prevention and Control

2.5.1. IPC Practices

Table 2.5.1a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
18.1.1 Facility has a staff member been designated as an infection prevention and control (n=180)	6	75	10	35.7	95	74.8	1	33.3	12	92.3	1	100	43	67.2	12	85.7	70	68.6	125	69.4
18.1.2 Patients routinely asked about cough when entering the facility (n=180)	7	87.5	26	92.9	126	99.2	3	100	13	100	1	100	63	98.4	14	100	99	97.1	176	97.8
18.1.3 Cough triage implemented at health facility (n=180)	6	75	12	42.9	97	76.4	1	33.3	10	76.9	1	100	39	60.9	13	92.9	75	73.5	127	70.6
18.1.4 Facility has a separate waiting area in the facility to isolate potentially infectious people (n=180)	6	75	8	28.6	89	70.1	2	66.7	9	69.2	1	100	35	54.7	11	78.6	69	67.6	115	63.9
18.1.5 Facility has a designated person assist with separation and triage of coughing patients (n=180)	5	62.5	5	17.9	78	61.4	1	33.3	7	53.8	1	100	29	45.3	8	57.1	60	58.8	97	53.9
18.1.6 Facility provides medical masks to presumptive and confirmed TB patients (n=180)	2	25	15	53.6	79	62.2	2	66.7	9	69.2	1	100	37	57.8	8	57.1	63	61.8	108	60
18.1.6.1 Medical masks consistently worn by presumptive and confirmed TB patients (n=108)	2	100	14	93.3	79	100	2	100	9	100	1	100	36	97.3	8	100	63	100	107	99.1

18.1.7 Facility has a system in place to screen and evaluate staff for TB disease (n=180)	6	75	9	32.1	91	71.7	1	33.3	12	92.3	0	0	46	71.9	11	78.6	62	60.8	119	66.1
18.1.8 Staff are offered an HIV test (when needed) (n=180)	8	100	28	100	115	90.6	3	100	13	100	1	100	58	90.6	13	92.9	97	95.1	168	93.3
18.1.9 Staff offered ART if HIV-positive (n=180)	6	75	16	57.1	80	63	3	100	9	69.2	1	100	44	68.8	5	35.7	66	64.7	115	63.9
18.1.10 Where HIV-positive staff receive ART (n=115)																				
From this facility	6	100	0	0	53	66.3	2	66.7	1	11.1	1	100	25	56.8	3	60	35	53	63	54.8
Referred out	0	0	14	87.5	25	31.3	1	33.3	8	88.9	0	0	15	34.1	2	40	31	47	48	41.7
Don't Know	0	0	0	1	1.3	0	0	0	0	0	1	2.3	0	0	0	0	1	0.9		
Other (specify)	0	2	12.5	1	1.3	0	0	0	0	0	3	6.8	0	0	0	0	3	2.6		
Total	6	100	16	100	80	100	3	100	9	100	1	100	44	100	5	100	66	100	115	100

2.5.2. IPC Infrastructure

Table 2.5.2a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
18.3.1 Running water (piped, bucket with tap or pour pitcher)	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100
18.3.2 Hand washing soap (may be liquid soap)	8	100	28	100	124	97.6	3	100	13	100	1	100	62	96.9	14	100	101	99	177	98.3
18.3.3 Alcohol-based hand rub	8	100	28	100	126	99.2	3	100	13	100	1	100	64	100	14	100	101	99	179	99.4
18.3.4 Medical waste receptacle (pedal bin) with lid and plastic bin liners	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100
18.3.5 Other waste receptacle	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100

18.3.6 Sharps container (i.e., safety box)	8	100	27	96.4	124	97.6	3	100	13	100	1	100	64	100	13	92.9	99	97.1	176	97.8
18.3.7 Disposable latex gloves	8	100	28	100	125	98.4	3	100	13	100	1	100	64	100	14	100	100	98	178	98.9
18.3.8 Disinfectant (e.g., chlorine, alcohol)	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100
18.3.9 Single use standard disposable syringes with needles or auto-disable syringe	8	100	26	92.9	124	97.6	3	100	13	100	1	100	61	95.3	13	92.9	101	99	175	97.2
18.3.10 Gowns	8	100	28	100	126	99.2	3	100	13	100	1	100	64	100	14	100	101	99	179	99.4
18.3.11 Eye protection/goggles or face protection	8	100	27	96.4	116	91.3	3	100	13	100	1	100	59	92.2	13	92.9	96	94.1	168	93.3
18.3.12 Injection safety precaution guidelines for standard precautions	6	75	15	53.6	104	81.9	3	100	10	76.9	1	100	50	78.1	9	64.3	80	78.4	139	77.2
18.3.13 Needle destroyer	0	0	3	10.7	15	11.8	0	0	2	15.4	0	0	3	4.7	0	0	17	16.7	20	11.1
18.3.14 Methylated spirit and glycerine 70:30	8	100	28	100	125	98.4	3	100	13	100	1	100	63	98.4	13	92.9	102	100	178	98.9
18.5.1 N-95 and/or FFP2 respirators readily available for staff	6	75	24	85.7	80	63	3	100	13	100	1	100	49	76.6	6	42.9	72	70.6	127	70.6
18.2.1 An updated and approved infection prevention and control plan	3	37.5	8	28.6	75	59.1	1	33.3	10	76.9	1	100	40	62.5	8	57.1	50	49	98	54.4
18.2.2 An annual TB infection prevention and control risk assessment	1	12.5	2	7.1	52	40.9	1	33.3	7	53.8	0	0	26	40.6	6	42.9	31	30.4	63	35
18.2.3 Supplies for coughing patients (tissues, surgical masks, etc.)	5	62.5	18	64.3	98	77.2	2	66.7	11	84.6	1	100	45	70.3	9	64.3	81	79.4	135	75
18.2.4 A confidential log for all staff with presumptive or confirmed TB	2	25	1	3.6	37	29.1	0	0	5	38.5	0	0	17	26.6	3	21.4	25	24.5	45	25

18.2.5 Patient waiting areas are either outdoors or indoors with access to continuous fresh air	7	87.5	20	71.4	119	93.7	3	100	12	92.3	1	100	59	92.2	12	85.7	91	89.2	162	90
Total	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100

2.5.3. TB screening of facility Staff

Table 2.5.3a

		Facility Type												Facility Location						Total	
		District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
18.1.7.1 Facility has any staff that have been diagnosed with active TB disease in the last 2 years (n=119)		1	16.7	2	22.2	14	15.4	1	100	6	50	--	--	12	26.1	0	0	12	19.4	24	20.2
18.7.1.1 Number of staff diagnosed with TB in the past 2 years (n=24)	Average	1	1	2	1	2	--	2	--	2	--	2	--	2	--	2	--	2	--	2	--
	Range	[1]	[1]	[0 - 10]	[1]	[1 - 4]	--	[1 - 4]	--	[0 - 10]	[0 - 10]										
	Total Facilities	1	2	14	1	6	--	12	--	12	--	12	--	12	--	12	--	12	--	24	--

2.6. Management of TB Services

2.6.1. Availability of Guidelines, Protocols, etc.

Table 2.6.1a

General TB Policies, Protocols, and Guidelines observed at the facility	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
10.1.1 Flowcharts or algorithms on TB screening (n=180)	3	37.5	11	39.3	83	65.4	3	100	10	76.9	0	0	43	67.2	8	57.1	59	57.8	110	61.1
10.1.2 Guidelines for diagnosis and treatment of TB among children (n=180)	3	37.5	21	75	101	79.5	3	100	11	84.6	1	100	53	82.8	9	64.3	78	76.5	140	77.8
10.1.3 Guidelines for TB infection control (n=180)	3	37.5	22	78.6	100	78.7	3	100	11	84.6	1	100	52	81.3	9	64.3	79	77.5	140	77.8
10.1.4 TB/HIV guidelines, i.e., management of HIV and TB coinfection (n=178)	3	37.5	20	74.1	103	81.7	3	100	10	76.9	0	0	52	81.3	6	46.2	81	80.2	139	78.1
10.1.5 Educational materials about TB i.e. posters on walls, leaflets, brochures (n=180)	3	37.5	22	78.6	110	86.6	3	100	11	84.6	0	0	51	79.7	12	85.7	86	84.3	149	82.8

Table 2.6.1b

TB Policies, Protocols, and Guidelines observed at diagnostic facilities	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
10.2.1 Flowcharts or algorithms on TB diagnosis (n=165)	4	50	12	80	117	93.6	3	100	11	84.6	0	0	55	91.7	11	84.6	81	88	147	89.1
10.2.2 Algorithm for laboratory testing of persons with presumptive TB (n=165)	3	37.5	7	46.7	84	67.2	3	100	9	69.2	0	0	39	65	6	46.2	61	66.3	106	64.2
10.2.3 Guidelines on the use of chest X-ray for TB screening and diagnosis (n=165)	4	50	13	86.7	94	75.2	3	100	11	84.6	1	100	49	81.7	7	53.8	70	76.1	126	76.4
10.2.4 Smear microscopy manual or guidelines (n=158)	4	66.7	10	90.9	115	92.7	3	100	12	92.3	1	100	55	93.2	11	84.6	79	91.9	145	91.8
10.2.5 Algorithms for GeneXpert (n=120)	1	25	4	36.4	36	40.4	3	100	12	92.3	--	--	30	65.2	3	27.3	23	36.5	56	46.7

Table 2.6.1c

TB Policies, Protocols, and Guidelines observed at treatment facilities	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
10.3.1 Essential drug or medicines list (n=174)	2	25	18	78.3	98	77.8	3	100	11	84.6	1	100	49	79	5	38.5	79	79.8	133	76.4
10.3.2 A training manual for DOT providers or volunteers (n=137)	2	66.7	10	58.8	55	53.4	0	0	6	50	0	0	22	45.8	4	57.1	47	57.3	73	53.3

10.3.3 Guidelines on clinical management of DR-TB (n=150)	3	75	13	68.4	79	71.2	3	100	11	84.6	--	--	47	83.9	4	40	58	69	109	72.7
10.3.4 Procedures on DR-TB patients management (SOP developed by VNTP) (n=150)	1	25	12	63.2	82	73.9	3	100	9	69.2	--	--	47	83.9	5	50	55	65.5	107	71.3
10.3.5 Guidelines on use of short regimens for DR-TB treatment (n=150)	2	50	14	73.7	78	70.3	3	100	11	84.6	--	--	48	85.7	4	40	56	66.7	108	72
10.3.6 Guidelines on providing palliative care to TB patients (n=150)	1	25	6	31.6	64	57.7	1	33.3	10	76.9	--	--	33	58.9	3	30	46	54.8	82	54.7

Table 2.6.1d

Table 2.6.10

TB Policies, Protocols, and Guidelines on LTBI	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
20V. 5.1 Flowcharts or algorithms on LTBI screening (n=180)	3	37.5	18	64.3	85	66.9	3	100	10	76.9	0	0	46	71.9	6	42.9	67	65.7	119	66.1
20V.5.2 Guidelines for diagnosis and treatment of LTBI (n=180)	4	50	21	75	97	76.4	3	100	11	84.6	0	0	54	84.4	6	42.9	76	74.5	136	75.6
20V.5.3 Algorithms for TST or IGRAs (n=180)	4	50	17	60.7	87	68.5	2	66.7	10	76.9	0	0	43	67.2	6	42.9	71	69.6	120	66.7
20V.5.4 LTBI treatment register (the yellow book) (n=180)	2	25	18	64.3	99	78	2	66.7	7	53.8	0	0	49	76.6	11	78.6	68	66.7	128	71.1
20V.5.5 Mantoux register and biology products management register (n=180)	3	37.5	14	50	88	69.3	1	33.3	6	46.2	0	0	39	60.9	11	78.6	62	60.8	112	62.2

2.6.2 Supervision and Feedback for Facility/Providers

Table 2.6.2a

Table 2.0.20

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
12.1 Supervisor from any upper-level office has visited health facility within the past 6 months (n=180)	8	100	26	92.9	120	94.5	2	66.7	12	92.3	0	0	59	92.2	12	85.7	97	95.1	168	93.3
Activities performed during the last supervisory visit to the facility (n=168)																				
12.1.2 Assess the pharmacy, e.g., drug stockout, expiry, records, etc.	7	87.5	22	84.6	114	95	2	100	12	100	--	--	56	94.9	12	100	89	91.8	157	93.5
12.1.3 Assess the laboratory, e.g. assess lab procedures, review lab records, assess TAT, etc.	7	87.5	21	80.8	113	94.2	2	100	12	100	--	--	56	94.9	12	100	87	89.7	155	92.3
12.1.4 Assess TB data, e.g., completeness, quality, and/or timely reporting of registers, treatment cards, quarterly or monthly reports, etc.	8	100	25	96.2	120	100	2	100	12	100	--	--	59	100	12	100	96	99	167	99.4
12.1.5 Discuss the performance of the facility based on TB service data	8	100	25	96.2	117	97.5	2	100	12	100	--	--	58	98.3	12	100	94	96.9	164	97.6
12.1.6 Complete the supervisory checklist	6	75	24	92.3	118	98.3	2	100	12	100	--	--	58	98.3	11	91.7	93	95.9	162	96.4
12.1.7 Provide a record of written comments or suggestions from their visit	7	87.5	23	88.5	114	95	2	100	11	91.7	--	--	56	94.9	12	100	89	91.8	157	93.5
Total	8	100	26	100	120	100	2	100	12	100	--	--	59	100	12	100	97	100	168	100

2.7. Capacity of TB Providers

2.7.1. Training –Facility Perspective

Table 2.7.1a

Table 2.7.10

New or refresher trainings/topics received by facility TB providers within the past 2 years	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
11.1 Screening algorithm for TB	7	87.5	23	82.1	115	90.6	3	100	11	84.6	0	0	60	93.8	13	92.9	86	84.3	159	88.3
11.2 Screening or diagnosis of TB based on X-rays	8	100	26	92.9	115	90.6	3	100	12	92.3	1	100	61	95.3	13	92.9	91	89.2	165	91.7
11.3 Diagnosis of TB based on clinical symptoms or examination (for adults)	8	100	27	96.4	122	96.1	3	100	13	100	0	0	63	98.4	13	92.9	97	95.1	173	96.1
11.4 Diagnosis of TB based on sputum tests using smear microscopy	7	87.5	25	89.3	122	96.1	3	100	13	100	1	100	64	100	13	92.9	94	92.2	171	95
11.5 Diagnosis of TB based on sputum tests using culture	6	75	15	53.6	81	63.8	1	33.3	13	100	1	100	46	71.9	8	57.1	63	61.8	117	65
11.6 Diagnosis of TB using Xpert	6	75	23	82.1	107	84.3	3	100	13	100	1	100	60	93.8	12	85.7	81	79.4	153	85
11.7 Management of children with presumptive TB	5	62.5	27	96.4	110	86.6	3	100	11	84.6	1	100	59	92.2	12	85.7	86	84.3	157	87.2
11.8 Prescription of drugs for TB treatment	8	100	24	85.7	120	94.5	3	100	13	100	0	0	62	96.9	13	92.9	93	91.2	168	93.3
11.9 Management of drug-susceptible TB (DS-TB) treatment	7	87.5	24	85.7	113	89	3	100	13	100	1	100	60	93.8	13	92.9	88	86.3	161	89.4
11.10 Screening and diagnosis of DR-TB	7	87.5	26	92.9	104	81.9	3	100	12	92.3	1	100	58	90.6	12	85.7	83	81.4	153	85
11.11 Management of DR-TB treatment	8	100	26	92.9	107	84.3	3	100	13	100	1	100	60	93.8	12	85.7	86	84.3	158	87.8
11.12 Management of TB/HIV coinfection	7	87.5	25	89.3	107	84.3	3	100	12	92.3	1	100	57	89.1	11	78.6	87	85.3	155	86.1
11.13 TB infection control	8	100	25	89.3	111	87.4	3	100	11	84.6	1	100	56	87.5	13	92.9	90	88.2	159	88.3
Total	8	100	28	100	127	100	3	100	13	100	1	100	64	100	14	100	102	100	180	100

2.7.2. Training –TB Provider Perspective

Table 2.7.2a

Table 2.7.2b	Facility Type												Provider Occupation								Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital		Nurse		Medical doctor/clinical officer		Other					
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
2.1.1 HIV testing and counseling for TB patients onsite (n=376)																						
No	11	50	6	16.7	71	26.7	1	20	17	38.6	1	33.3	37	46.8	64	25.1	6	14.3	107	28.5		
Yes, over 24 months ago	2	9.1	10	27.8	86	32.3	0	0	18	40.9	0	0	22	27.8	79	31	15	35.7	116	30.9		
Yes, within the last 24 months	9	40.9	20	55.6	109	41	4	80	9	20.5	2	66.7	20	25.3	112	43.9	21	50	153	40.7		
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100		
2.1.2 Referral for HIV testing and counseling for TB patients (n=376)																						
No	11	50	6	16.7	74	27.8	1	20	14	31.8	1	33.3	42	53.2	59	23.1	6	14.3	107	28.5		
Yes, over 24 months ago	1	4.5	13	36.1	77	28.9	0	0	17	38.6	0	0	18	22.8	76	29.8	14	33.3	108	28.7		
Yes, within the last 24 months	10	45.5	17	47.2	115	43.2	4	80	13	29.5	2	66.7	19	24.1	120	47.1	22	52.4	161	42.8		
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100		
2.1.3 Preventive treatment for TB infection (INH + Pyridoxine), either on site or via referral (n=376)																						
No	11	50	3	8.3	68	25.6	1	20	13	29.5	1	33.3	39	49.4	49	19.2	9	21.4	97	25.8		
Yes, over 24 months ago	2	9.1	8	22.2	62	23.3	0	0	11	25	1	33.3	18	22.8	57	22.4	9	21.4	84	22.3		
Yes, within the last 24 months	9	40.9	25	69.4	135	50.8	4	80	20	45.5	1	33.3	21	26.6	149	58.4	24	57.1	194	51.6		
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	1	1.3	0	0	0	0	1	0.3		
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100		

2.1.4 HIV care and treatment services to TB/HIV coinfecting patients (n=376)																				
No	10	45.5	7	19.4	102	38.3	3	60	22	50	1	33.3	50	63.3	81	31.8	14	33.3	145	38.6
Yes, over 24 months ago	2	9.1	12	33.3	62	23.3	0	0	14	31.8	1	33.3	18	22.8	61	23.9	12	28.6	91	24.2
Yes, within the last 24 months	10	45.5	17	47.2	102	38.3	2	40	8	18.2	1	33.3	11	13.9	113	44.3	16	38.1	140	37.2
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.1.4.1 ART for TB/HIV coinfecting patients (n=231)																				
No	1	8.3	10	34.5	49	29.9	0	0	9	40.9	0	0	13	44.8	51	29.3	5	17.9	69	29.9
Yes, over 24 months ago	2	16.7	8	27.6	52	31.7	0	0	9	40.9	1	50	10	34.5	50	28.7	12	42.9	72	31.2
Yes, within the last 24 months	8	66.7	11	37.9	63	38.4	2	100	4	18.2	1	50	6	20.7	72	41.4	11	39.3	89	38.5
No response	1	8.3	0	0	0	0	0	0	0	0	0	0	0	0	1	0.6	0	0	1	0.4
Total	12	100	29	100	164	100	2	100	22	100	2	100	29	100	174	100	28	100	231	100
2.1.4.2 Identification of TB/HIV drug interactions (n=231)																				
No	2	16.7	9	31	43	26.2	0	0	5	22.7	0	0	12	41.4	41	23.6	6	21.4	59	25.5
Yes, over 24 months ago	2	16.7	9	31	50	30.5	0	0	8	36.4	1	50	11	37.9	49	28.2	10	35.7	70	30.3
Yes, within the last 24 months	8	66.7	11	37.9	70	42.7	2	100	9	40.9	1	50	6	20.7	84	48.3	11	39.3	101	43.7
No response	0	0	0	0	1	0.6	0	0	0	0	0	0	0	0	0	0	1	3.6	1	0.4
Total	12	100	29	100	164	100	2	100	22	100	2	100	29	100	174	100	28	100	231	100
2.1.4.3 Identification of immune reconstitution inflammatory syndrome (IRIS) (n=231)																				
No	7	58.3	18	62.1	88	53.7	1	50	7	31.8	0	0	21	72.4	85	48.9	15	53.6	121	52.4
Yes, over 24 months ago	0	0	3	10.3	31	18.9	0	0	7	31.8	1	50	4	13.8	35	20.1	3	10.7	42	18.2
Yes, within the last 24 months	5	41.7	8	27.6	45	27.4	1	50	8	36.4	1	50	4	13.8	54	31	10	35.7	68	29.4
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	12	100	29	100	164	100	2	100	22	100	2	100	29	100	174	100	28	100	231	100
2.1.4.4 CPT for TB/HIV coinfecting patients (n=231)																				
No	5	41.7	11	37.9	52	31.7	0	0	8	36.4	0	0	13	44.8	55	31.6	8	28.6	76	32.9
Yes, over 24 months ago	1	8.3	9	31	53	32.3	0	0	7	31.8	1	50	9	31	53	30.5	9	32.1	71	30.7

Yes, within the last 24 months	6	50	9	31	59	36	2	100	7	31.8	1	50	7	24.1	66	37.9	11	39.3	84	36.4
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	12	100	29	100	164	100	2	100	22	100	2	100	29	100	174	100	28	100	231	100
2.1.4.5 Viral load testing for TB/HIV coinfecting patients (n=231)																				
No	4	33.3	13	44.8	67	40.9	0	0	9	40.9	0	0	15	51.7	67	38.5	11	39.3	93	40.3
Yes, over 24 months ago	0	0	8	27.6	43	26.2	0	0	9	40.9	1	50	8	27.6	46	26.4	7	25	61	26.4
Yes, within the last 24 months	8	66.7	8	27.6	53	32.3	2	100	4	18.2	1	50	6	20.7	60	34.5	10	35.7	76	32.9
No response	0	0	0	0	1	0.6	0	0	0	0	0	0	0	0	1	0.6	0	0	1	0.4
Total	12	100	29	100	164	100	2	100	22	100	2	100	29	100	174	100	28	100	231	100
2.2.1 Diagnosis of TB by clinical symptoms and signs (n=376)																				
No	5	22.7	1	2.8	34	12.8	0	0	5	11.4	0	0	31	39.2	13	5.1	1	2.4	45	12
Yes, over 24 months ago	4	18.2	6	16.7	51	19.2	0	0	11	25	0	0	18	22.8	42	16.5	12	28.6	72	19.1
Yes, within the last 24 months	13	59.1	29	80.6	181	68	5	100	28	63.6	3	100	30	38	200	78.4	29	69	259	68.9
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.2 Diagnosis of TB by sputum smear microscopy (n=376)																				
No	9	40.9	2	5.6	67	25.2	0	0	8	18.2	0	0	44	55.7	35	13.7	7	16.7	86	22.9
Yes, over 24 months ago	3	13.6	6	16.7	38	14.3	0	0	11	25	0	0	12	15.2	39	15.3	7	16.7	58	15.4
Yes, within the last 24 months	10	45.5	28	77.8	161	60.5	5	100	25	56.8	3	100	23	29.1	181	71	28	66.7	232	61.7
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.3 Diagnosis of TB by X-ray (n=376)																				
No	8	36.4	5	13.9	58	21.8	0	0	10	22.7	0	0	50	63.3	24	9.4	7	16.7	81	21.5
Yes, over 24 months ago	4	18.2	6	16.7	37	13.9	0	0	8	18.2	0	0	7	8.9	39	15.3	9	21.4	55	14.6
Yes, within the last 24 months	10	45.5	25	69.4	171	64.3	5	100	26	59.1	3	100	22	27.8	192	75.3	26	61.9	240	63.8
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100

2.2.4.1 Diagnosis of TB by Xpert MTB/RIF (n=376)																				
No	12	54.5	7	19.4	91	34.2	0	0	6	13.6	1	33.3	50	63.3	57	22.4	10	23.8	117	31.1
Yes, over 24 months ago	3	13.6	3	8.3	26	9.8	0	0	9	20.5	0	0	9	11.4	27	10.6	5	11.9	41	10.9
Yes, within the last 24 months	7	31.8	26	72.2	148	55.6	5	100	29	65.9	2	66.7	20	25.3	170	66.7	27	64.3	217	57.7
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.4.2 Diagnosis of TB by Xpert Ultra (n=376)																				
No	16	72.7	14	38.9	137	51.5	0	0	16	36.4	2	66.7	63	79.7	102	40	20	47.6	185	49.2
Yes, over 24 months ago	2	9.1	2	5.6	20	7.5	0	0	5	11.4	0	0	4	5.1	21	8.2	4	9.5	29	7.7
Yes, within the last 24 months	4	18.2	20	55.6	108	40.6	5	100	23	52.3	1	33.3	12	15.2	131	51.4	18	42.9	161	42.8
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.4.3 Diagnosis of TB by Xpert MTB/XDR (n=376)																				
No	16	72.7	11	30.6	155	58.3	1	20	19	43.2	2	66.7	64	81	121	47.5	19	45.2	204	54.3
Yes, over 24 months ago	2	9.1	2	5.6	15	5.6	0	0	4	9.1	0	0	2	2.5	17	6.7	4	9.5	23	6.1
Yes, within the last 24 months	4	18.2	23	63.9	92	34.6	4	80	20	45.5	1	33.3	12	15.2	113	44.3	19	45.2	144	38.3
No response	0	0	0	0	4	1.5	0	0	1	2.3	0	0	1	1.3	4	1.6	0	0	5	1.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.4.5 Diagnosis of TB by TB LAMP (n=376)																				
No	18	81.8	22	61.1	216	81.2	3	60	34	77.3	2	66.7	74	93.7	190	74.5	31	73.8	295	78.5
Yes, over 24 months ago	0	0	2	5.6	9	3.4	0	0	1	2.3	0	0	0	0	9	3.5	3	7.1	12	3.2
Yes, within the last 24 months	4	18.2	12	33.3	39	14.7	2	40	8	18.2	1	33.3	5	6.3	53	20.8	8	19	66	17.6
No response	0	0	0	0	2	0.8	0	0	1	2.3	0	0	0	0	3	1.2	0	0	3	0.8
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.4.6 Diagnosis of TB by MDR/TB or XDR=TB LPA (n=376)																				
No	18	81.8	14	38.9	161	60.5	0	0	15	34.1	2	66.7	60	75.9	133	52.2	17	40.5	210	55.9
Yes, over 24 months ago	0	0	4	11.1	19	7.1	0	0	7	15.9	0	0	2	2.5	24	9.4	4	9.5	30	8

Yes, within the last 24 months	4	18.2	18	50	85	32	5	100	22	50	1	33.3	17	21.5	97	38	21	50	135	35.9
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.5 Diagnosis of TB by urine LAM Ag (n=376)																				
No	18	81.8	21	58.3	216	81.2	3	60	36	81.8	1	33.3	74	93.7	190	74.5	31	73.8	295	78.5
Yes, over 24 months ago	0	0	4	11.1	12	4.5	0	0	1	2.3	0	0	0	0	14	5.5	3	7.1	17	4.5
Yes, within the last 24 months	4	18.2	11	30.6	37	13.9	2	40	7	15.9	2	66.7	5	6.3	50	19.6	8	19	63	16.8
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.6 Diagnosis of TB in children using stool-based testing (n=376)																				
No	18	81.8	14	38.9	153	57.5	0	0	13	29.5	2	66.7	60	75.9	121	47.5	19	45.2	200	53.2
Yes, over 24 months ago	1	4.5	2	5.6	16	6	0	0	8	18.2	0	0	5	6.3	19	7.5	3	7.1	27	7.2
Yes, within the last 24 months	3	13.6	20	55.6	96	36.1	5	100	23	52.3	1	33.3	14	17.7	114	44.7	20	47.6	148	39.4
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.7 Diagnosis of drug-resistant TB (n=376)																				
No	14	63.6	7	19.4	95	35.7	0	0	10	22.7	2	66.7	51	64.6	71	27.8	6	14.3	128	34
Yes, over 24 months ago	1	4.5	7	19.4	45	16.9	0	0	7	15.9	0	0	7	8.9	44	17.3	9	21.4	60	16
Yes, within the last 24 months	7	31.8	22	61.1	125	47	5	100	27	61.4	1	33.3	21	26.6	139	54.5	27	64.3	187	49.7
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.2.7.1 TB culture (solid or liquid) or growth medium (n=247)																				
No	6	75	17	58.6	120	70.6	0	0	21	61.8	0	0	18	64.3	121	66.1	25	69.4	164	66.4
Yes, over 24 months ago	1	12.5	5	17.2	13	7.6	0	0	5	14.7	0	0	3	10.7	17	9.3	4	11.1	24	9.7
Yes, within the last 24 months	1	12.5	7	24.1	37	21.8	5	100	8	23.5	1	100	7	25	45	24.6	7	19.4	59	23.9
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	8	100	29	100	170	100	5	100	34	100	1	100	28	100	183	100	36	100	247	100

2.2.7.2 Line probe assays (LPAs) (n=247)																				
No	7	87.5	18	62.1	112	65.9	1	20	18	52.9	0	0	19	67.9	112	61.2	25	69.4	156	63.2
Yes, over 24 months ago	0	0	4	13.8	15	8.8	0	0	5	14.7	0	0	3	10.7	18	9.8	3	8.3	24	9.7
Yes, within the last 24 months	1	12.5	7	24.1	42	24.7	4	80	11	32.4	1	100	6	21.4	52	28.4	8	22.2	66	26.7
No response	0	0	0	0	1	0.6	0	0	0	0	0	0	0	0	1	0.5	0	0	1	0.4
Total	8	100	29	100	170	100	5	100	34	100	1	100	28	100	183	100	36	100	247	100
2.2.8 Referral for drug (n=376)																				
No	15	68.2	6	16.7	88	33.1	0	0	22	50	1	33.3	43	54.4	79	31	10	23.8	132	35.1
Yes, over 24 months ago	2	9.1	9	25	47	17.7	0	0	2	4.5	0	0	11	13.9	41	16.1	8	19	60	16
Yes, within the last 24 months	5	22.7	21	58.3	130	48.9	5	100	19	43.2	2	66.7	25	31.6	134	52.5	23	54.8	182	48.4
No response	0	0	0	0	1	0.4	0	0	1	2.3	0	0	0	0	1	0.4	1	2.4	2	0.5
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.1 Prescription of drugs for TB treatment (n=376)																				
No	9	40.9	9	25	78	29.3	0	0	15	34.1	1	33.3	58	73.4	40	15.7	14	33.3	112	29.8
Yes, over 24 months ago	3	13.6	8	22.2	31	11.7	0	0	5	11.4	0	0	5	6.3	38	14.9	4	9.5	47	12.5
Yes, within the last 24 months	10	45.5	19	52.8	157	59	5	100	24	54.5	2	66.7	16	20.3	177	69.4	24	57.1	217	57.7
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.2 Direct observation of treatment (DOT) (n=376)																				
No	13	59.1	9	25	82	30.8	2	40	8	18.2	0	0	40	50.6	61	23.9	13	31	114	30.3
Yes, over 24 months ago	2	9.1	12	33.3	44	16.5	0	0	13	29.5	0	0	13	16.5	51	20	7	16.7	71	18.9
Yes, within the last 24 months	7	31.8	15	41.7	139	52.3	3	60	23	52.3	3	100	26	32.9	142	55.7	22	52.4	190	50.5
No response	0	0	0	0	1	0.4	0	0	0	0	0	0	0	0	1	0.4	0	0	1	0.3
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.3 Video DOT (n=376)																				
No	19	86.4	27	75	208	78.2	4	80	29	65.9	2	66.7	62	78.5	192	75.3	35	83.3	289	76.9
Yes, over 24 months ago	1	4.5	6	16.7	14	5.3	0	0	8	18.2	0	0	4	5.1	22	8.6	3	7.1	29	7.7
Yes, within the last 24 months	2	9.1	3	8.3	44	16.5	1	20	7	15.9	1	33.3	13	16.5	41	16.1	4	9.5	58	15.4

No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.4 TB treatment follow-up services, e.g., phone calls or home visits to TB patients (n=376)																				
No	10	45.5	6	16.7	90	33.8	0	0	18	40.9	2	66.7	36	45.6	82	32.2	8	19	126	33.5
Yes, over 24 months ago	3	13.6	8	22.2	43	16.2	0	0	8	18.2	0	0	15	19	42	16.5	5	11.9	62	16.5
Yes, within the last 24 months	9	40.9	22	61.1	131	49.2	5	100	18	40.9	1	33.3	28	35.4	130	51	28	66.7	186	49.5
No response	0	0	0	0	2	0.8	0	0	0	0	0	0	0	0	1	0.4	1	2.4	2	0.5
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.5 Identification of and referral for patients who fail treatment (n=376)																				
No	8	36.4	11	30.6	89	33.5	0	0	12	27.3	1	33.3	41	51.9	72	28.2	8	19	121	32.2
Yes, over 24 months ago	4	18.2	8	22.2	40	15	0	0	10	22.7	0	0	10	12.7	45	17.6	7	16.7	62	16.5
Yes, within the last 24 months	10	45.5	17	47.2	137	51.5	5	100	22	50	2	66.7	28	35.4	138	54.1	27	64.3	193	51.3
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.6 Treatment of drug-resistant TB (n=376)																				
No	11	50	11	30.6	101	38	0	0	13	29.5	1	33.3	46	58.2	80	31.4	11	26.2	137	36.4
Yes, over 24 months ago	4	18.2	7	19.4	37	13.9	0	0	6	13.6	0	0	9	11.4	41	16.1	4	9.5	54	14.4
Yes, within the last 24 months	7	31.8	18	50	128	48.1	5	100	25	56.8	2	66.7	24	30.4	134	52.5	27	64.3	185	49.2
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100
2.3.7 Referral for drug-resistant TB treatment (n=376)																				
No	8	36.4	12	33.3	83	31.2	0	0	25	56.8	1	33.3	39	49.4	78	30.6	12	28.6	129	34.3
Yes, over 24 months ago	4	18.2	7	19.4	42	15.8	0	0	4	9.1	0	0	11	13.9	41	16.1	5	11.9	57	15.2
Yes, within the last 24 months	10	45.5	17	47.2	141	53	5	100	15	34.1	2	66.7	29	36.7	136	53.3	25	59.5	190	50.5
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	22	100	36	100	266	100	5	100	44	100	3	100	79	100	255	100	42	100	376	100

2.8. Health Insurance Reimbursement Coverage

2.8.1. Service coverage (by health insurance scheme)

Table 2.8.1a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
19V.1 TB services covered by the HI scheme at this facility (n=152)	8	100	2	66.7	124	98.4	1	100	13	100	1	100	52	96.3	13	100	84	98.8	149	98
19V.1.1 Year that facility start covering TB services under the HI scheme (n=149)																				
2004	0	0	0	0	0	0	0	0	1	7.7	0	0	1	1.9	0	0	0	0	1	0.7
2006	0	0	0	0	0	0	0	0	1	7.7	0	0	1	1.9	0	0	0	0	1	0.7
2021	0	0	0	0	0	0	0	0	1	7.7	0	0	1	1.9	0	0	0	0	1	0.7
2022	8	100	2	100	109	87.9	1	100	9	69.2	1	100	48	92.3	11	84.6	71	84.5	130	87.2
2023	0	0	0	0	15	12.1	0	0	1	7.7	0	0	1	1.9	2	15.4	13	15.5	16	10.7

Table 2.8.1b

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
19V.2 TB services covered by HI at health facility																				
Health check-ups/physician office visits	3	37.5	0	0	67	54	0	0	7	53.8	0	0	22	42.3	3	23.1	52	61.9	77	51.7
1st line drugs	8	100	2	100	123	99.2	1	100	13	100	1	100	51	98.1	13	100	84	100	148	99.3
Diagnostic tests (other than X-ray)	5	62.5	1	50	99	79.8	1	100	13	100	1	100	45	86.5	8	61.5	67	79.8	120	80.5
X-ray	8	100	1	50	112	90.3	1	100	13	100	1	100	45	86.5	11	84.6	80	95.2	136	91.3
Total	8	100	2	100	124	100	1	100	13	100	1	100	52	100	13	100	84	100	149	100

Table 2.8.1c

Table 21a.1c

	Type of TB				Total	
	Yes, DS TB		Yes, DR TB		No.	%
	No.	%	No.	%		
13V.1 Do you currently have health insurance coverage?						
Yes, compulsory social health insurance	51	8	5	9.1	56	8
Yes, voluntary social health insurance	389	60.7	37	67.3	426	61.2
Yes, I have HI through preferential policies (e.g., poor households, children, the elderly)	188	29.3	9	16.4	197	28.3
Yes, private health insurance	14	2.2	2	3.6	16	2.3
No/Uninsured	5	0.8	2	3.6	7	1
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
13V.2 How did you pay for the TB services you received during your most recent visit to the facility?						
Out of pocket (full payment)	7	1.1	4	7.3	11	1.6
Co-payment	239	37.3	13	23.6	252	36.2
Reimbursed in full by health insurance	382	59.6	30	54.5	412	59.2
Other (specify)	13	2	8	14.5	21	3
Total	641	100	55	100	696	100

Table 2.8.1d

Which of the following TB services that you received during your most recent visit to the facility) were covered, in total or in part, by your health insurance?	Type of TB				Total	
	Yes, DS TB		Yes, DR TB			
	No.	%	No.	%	No.	%
13V.3.1 Health check-ups/physician office visits						
Yes, it was covered by health insurance	365	58.8	31	72.1	396	59.6
No, it was not covered by health insurance	10	1.6	2	4.7	12	1.8
Don't use	246	39.6	10	23.3	256	38.6
13V.3.2 1st line drugs						
Yes, it was covered by health insurance	503	81	28	65.1	531	80
No, it was not covered by health insurance	5	0.8	2	4.7	7	1.1
Don't use	113	18.2	13	30.2	126	19
13V.3.3 Diagnostic tests						
Yes, it was covered by health insurance	415	66.8	34	79.1	449	67.6
No, it was not covered by health insurance	9	1.4	0	0	9	1.4
Don't use	197	31.7	9	20.9	206	31
13V.3.4 X-ray						
Yes, it was covered by health insurance	299	48.1	30	69.8	329	49.5
No, it was not covered by health insurance	19	3.1	0	0	19	2.9
Don't use	303	48.8	13	30.2	316	47.6
13V.3.5 Don't know						
Yes, it was covered by health insurance	7	1.1	2	4.7	9	1.4
No, it was not covered by health insurance	14	2.3	3	7	17	2.6
Don't use	600	96.6	38	88.4	638	96.1
13V.4 Why did you not use HI to pay for the TB services you received? (for any TB services are not covered by health insurance)						
The facility is not covered by the HI scheme	4	9.3	0	0	4	7.7
HI does not cover the TB services that I received	12	27.9	4	44.4	16	30.8
I did not know that I could use HI to pay for my services	3	7	0	0	3	5.8
I do not want to use HI for TB services	1	2.3	0	0	1	1.9

Other (specify)	9	20.9	3	33.3	12	23.1
No response	14	32.6	2	22.2	16	30.8
Total	43	100	9	100	52	100
13V.5 Why don't you currently have health insurance?						
I do not need health insurance	1	20	0	0	1	14.3
I cannot afford health insurance	1	20	0	0	1	14.3
Other (specify)	3	60	2	100	5	71.4
Total	5	100	2	100	7	100

2.8.2. Changes noticed since implementation of HI at health facility

Table 2.8.2a

Table 2.6.2d

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
19V.4 Facility has noticed an increase in loss-to-follow-up or drop-out of patients on treatment since the HI scheme was introduced (n=152)	2	25	1	33.3	37	29.4	0	0	3	23.1	0	0	19	35.2	3	23.1	21	24.7	43	28.3
19V.5 TB drugs procured through the central bidding process have been uploaded/assigned to your facility's account in the health insurance portal (n=149)	1	12.5	1	50	52	41.9	0	0	7	53.8	0	0	24	46.2	3	23.1	34	40.5	61	40.9
19V.6 Facility has experienced any challenges or barriers in including TB services under the HI scheme (n=149)	4	50	2	100	74	59.7	1	100	7	53.8	1	100	35	67.3	8	61.5	46	54.8	89	59.7
19V.7 Facility has experienced any challenges in getting reimbursed for the services it has provided by the HI provider (n=149)	0	0	0	0	43	34.7	0	0	8	61.5	0	0	20	38.5	6	46.2	25	29.8	51	34.2

2.8.3. Challenges of Health Insurance Scheme experienced by Health Facility

Table 2.8.3a

	Facility Type												Facility Location						Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two-function)		CDC		Lung Hospital		Provincial General Hospital		Urban		Peri-urban		Rural			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
19V.8 Reasons why TB service at your facility are not covered under the HI scheme at facility																				
Facility does not meet the requirements to sign a contract with the HI provider	--	--	19	73.1	1	33.3	2	100	--	--	--	--	8	66.7	1	100	13	72.2	22	71
There is a lack of qualified health staff to provide TB services at the facility according to the HI guidelines	--	--	3	11.5	0	0	0	0	--	--	--	--	1	8.3	0	0	2	11.1	3	9.7
There was a delay in signing the contract with HI provider	--	--	0	0	1	33.3	0	0	--	--	--	--	1	8.3	0	0	0	0	1	3.2
Other (specify)	--	--	4	15.4	1	33.3	0	0	--	--	--	--	2	16.7	0	0	3	16.7	5	16.1
Total	--	--	26	100	3	100	2	100	--	--	--	--	12	100	1	100	18	100	31	100

3 Process Indicators

3.1. Provider TB Casement Management

3.1.1. Establishing Patient Rapport

Table 3.1.1a

	Facility Type												Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
The interactions with TB patients that the providers listed by themselves (n=376)														
4.1.1 Be consistent in what is done and told to the patient	12	54.5	16	44.4	109	41	1	20	20	45.5	3	100	161	42.8
4.1.2 Be flexible in meeting the patient's needs	8	36.4	18	50	126	47.4	0	0	20	45.5	3	100	175	46.5
4.1.3 Communicate clearly	19	86.4	34	94.4	248	93.2	5	100	43	97.7	3	100	352	93.6
4.1.4 Have an open mind about the patient's cultural beliefs	15	68.2	20	55.6	189	71.1	3	60	20	45.5	3	100	250	66.5
4.1.5 Listen carefully to the patient	20	90.9	19	52.8	209	78.6	3	60	33	75	3	100	287	76.3
4.1.6 Recognize and address the patient's fears about the illness	16	72.7	17	47.2	147	55.3	1	20	21	47.7	3	100	205	54.5
4.1.7 Suggest behavior changes respectfully	12	54.5	17	47.2	101	38	0	0	18	40.9	3	100	151	40.2
4.1.8 Treat the patient with dignity and respect	14	63.6	23	63.9	151	56.8	2	40	28	63.6	3	100	221	58.8

3.1.2. Patient Assessment

Table 3.1.2a

Table 3.1.2a

	Facility Type												Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
As part of the initial patient assessment to determine their understanding of TB, what do you ask the patient to tell or explain to you? (n=376)														
4.2.1 Patient's previous medical/psychosocial history	17	77.3	28	77.8	206	77.4	5	100	36	81.8	3	100	295	78.5
4.2.2 Attitudes/beliefs towards TB	12	54.5	16	44.4	100	37.6	4	80	20	45.5	2	66.7	154	41
4.2.3 Knowledge of TB	14	63.6	18	50	147	55.3	3	60	28	63.6	2	66.7	212	56.4
4.2.4 Ability to follow the TB treatment plan	12	54.5	24	66.7	146	54.9	4	80	17	38.6	3	100	206	54.8

4.2.5 Potential barriers to treatment, e.g., lack of transportation, TB medications will be too expensive, etc.	15	68.2	24	66.7	175	65.8	1	20	25	56.8	3	100	243	64.6
4.2.6 Resources, e.g., family, other social support, finances	11	50	19	52.8	107	40.2	3	60	22	50	3	100	165	43.9
4.2.7 Other (specify)	1	4.5	5	13.9	29	10.9	1	20	3	6.8	0	0	39	10.4

3.2. TB Provider Knowledge & Practice

Table 3.2a

Table 5.2a

	Facility Type												Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I would like to ask you some questions about your knowledge of preventing transmission of TB within the facility. (n=376)														
5.1.1 Have you ever received any training on TB infection control?	11	50	31	86.1	192	72.2	5	100	40	90.9	2	66.7	281	74.7
5.2.1 Should doors and windows be left open whenever a patient or presumed or confirmed to have TB is in the room?	21	95.5	35	97.2	252	94.7	5	100	44	100	3	100	360	95.7
5.2.2 Can fans (ventilators) be used in TB wards to reduce the transmission of TB?	18	81.8	31	86.1	227	85.3	5	100	43	97.7	3	100	327	87
5.2.3 Should presumed or confirmed TB patients be separated from other patients?	19	86.4	32	88.9	217	81.6	4	80	40	90.9	3	100	315	83.8
5.2.4 Should health care providers minimize the time TB patients spend in the health facility?	15	68.2	17	47.2	98	36.8	2	40	13	29.5	3	100	148	39.4
5.2.5 Can surgical masks protect health care providers from inhaling the TB bacteria?	10	45.5	22	61.1	138	51.9	2	40	24	54.5	2	66.7	198	52.7
5.2.6 Can the use of respiratory protection, such as N95 particulate respirators, by health care providers protect them from inhaling the TB bacteria?	19	86.4	33	91.7	231	86.8	5	100	34	77.3	3	100	325	86.4
What do you do whenever you are with presumed or confirmed TB patients and/or working in the TB wards? (n=376)														
5.3.1 Use a mask/respirator whenever treating TB presumptive of confirmed patients	22	100	35	97.2	263	98.9	4	80	44	100	3	100	371	98.7
5.3.2 Give priority to coughing patients, i.e. attend to patients who are coughing first	15	68.2	33	91.7	212	79.7	2	40	28	63.6	2	66.7	292	77.7
5.3.3 Educate TB patients on cough etiquette, i.e. covering their mouth with hand, tissue, or elbow	22	100	35	97.2	262	98.5	5	100	42	95.5	2	66.7	368	97.9

while coughing or sneezing, not spitting on the floor, etc.														
5.3.4 Turn on fans to exhaust air outside the room, or blow air in the direction away from others while treating TB presumptive or confirmed cases	21	95.5	32	88.9	237	89.1	5	100	41	93.2	3	100	339	90.2
5.3.5 Request for TB diagnostic testing if the patient is symptomatic	22	100	36	100	260	97.7	5	100	43	97.7	2	66.7	368	97.9
5.3.6 Always screen all family members of confirmed TB patients for TB symptoms	14	63.6	32	88.9	220	82.7	5	100	35	79.5	2	66.7	308	81.9
5.3.7 Discuss with family members or those living with your TB patients, basic information and skills to protect household members and contacts from infection	17	77.3	35	97.2	248	93.2	5	100	37	84.1	2	66.7	344	91.5

3.3. Patient-Provider Interactions

3.3.1. Patient Experience at Health Facility

Table 3.3.1a

	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
Next, I would like to ask you about practices related to your disease.						
4.1 Were you examined by a healthcare provider at this facility during your first visit for your disease?	552	86.1	50	90.9	602	86.5
4.2 Has a healthcare provider at this facility talked with people you have close contact with, i.e., members of your family or those living with you, about how to prevent the spread of this disease from one person to another?	502	78.3	50	90.9	552	79.3
4.3 Were your family or close contacts examined for this disease?	301	47	43	78.2	344	49.4
4.3.1 Have you been told where to have your family or close contacts evaluated for this disease?	153	45	4	33.3	157	44.6

Table 3.3.1b

	Type of TB				Total	
	Yes, DS TB		Yes, DR TB			
	No.	%	No.	%	No.	%
Next, I would like to ask you about your face-to-face meetings with healthcare providers at this facility.						
8.1 During your visits to this facility, do the healthcare providers usually explain things in a way you can understand?	606	94.5	52	94.5	658	94.5
8.2 During your visits to this facility, do the healthcare providers listen to your opinion and ideas on the best way to follow your treatment?	605	94.4	53	96.4	658	94.5
8.3 Do the healthcare providers at this facility discuss your status or progress with you at every scheduled appointment?	579	90.3	51	92.7	630	90.5
8.4 During your visits to this facility, do you think the healthcare providers give you a chance to ask questions about anything that concerns you?	584	91.1	52	94.5	636	91.4
8.5 During your visits to this facility, do you usually have enough time to discuss your health needs with the healthcare providers?	587	91.6	49	89.1	636	91.4
8.6 During your visits to this facility, do the healthcare providers tell you how this disease can affect your everyday life?	518	80.8	50	90.9	568	81.6
8.7 Do the healthcare providers at this facility address your worries about your disease seriously when you visit the facility?	564	88	51	92.7	615	88.4
8.8 During your visits to this facility, do the healthcare providers listen carefully to you?	605	94.4	53	96.4	658	94.5
8.9 During your visits to this facility, do the healthcare providers explain how to cope with your problems?	571	89.1	50	90.9	621	89.2
8.10 During your visits to this facility, do you worry that other patients can hear your conversation with your healthcare providers?	112	17.5	7	12.7	119	17.1

Table 3.3.1c

	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
10.3 Which of the following services do you think would help you the most in continuing and completing your treatment, regardless of whether it is currently offered by this facility?						
10.3.1 Free TB medicines (does not include medicines patients get through HI)	563	87.8	52	94.5	615	88.4
10.3.2 Home-based treatment	453	70.7	40	72.7	493	70.8
10.3.3 Nutritional support/food basket	421	65.7	41	74.5	462	66.4
10.3.4 Rehabilitation services	343	53.5	31	56.4	374	53.7
10.3.5 Transport assistance	368	57.4	45	81.8	413	59.3
10.3.6 Small group TB health education session	391	61	41	74.5	432	62.1
10.3.7 One-on-one counseling (face-to-face) by medical staff (doctor or nurse)	560	87.4	51	92.7	611	87.8
10.3.8 One-on-one peer counseling (face-to-face) by either a lay counselor or a cured TB patient	403	62.9	39	70.9	442	63.5
10.3.9 Meeting with a social worker	335	52.3	32	58.2	367	52.7
10.3.10 Meeting with a psychologist	326	50.9	33	60	359	51.6

Table 3.3.1d

Table 3.3.1a

	Facility Type												Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
What do you do when a patient misses their treatment? (n=362)														
4.5.1 Advise them to return for treatment	13	68.4	19	65.5	139	53.1	4	80	21	47.7	2	66.7	198	54.7
4.5.2 Counsel and continue treatment from where they stopped	15	78.9	11	37.9	93	35.5	3	60	14	31.8	2	66.7	138	38.1
4.5.3 Counsel and repeat lab investigation	11	57.9	10	34.5	74	28.2	2	40	13	29.5	2	66.7	112	30.9
4.5.4 Follow up and track by contacting their school or workplace or family	11	57.9	8	27.6	69	26.3	1	20	13	29.5	0	0	102	28.2
4.5.5 Follow up and track by home visit	5	26.3	10	34.5	119	45.4	1	20	10	22.7	0	0	145	40.1
4.5.6 Follow up and track by phone	16	84.2	28	96.6	231	88.2	5	100	29	65.9	0	0	309	85.4
4.5.7 Follow up and track by SMS	7	36.8	7	24.1	80	30.5	0	0	9	20.5	0	0	103	28.5
4.5.8 Record missed day and extend treatment	11	57.9	9	31	69	26.3	1	20	12	27.3	0	0	102	28.2
4.5.9 Other (specify)	2	10.5	6	20.7	84	32.1	2	40	10	22.7	0	0	104	28.7

3.3.2. Information provided to TB patients (provider perspective)

Table 3.3.2a

Table 3.3.2a

What type of information or topics, excluding TB/HIV, are discussed with patients during diagnosis and treatment visits? (n=376)	Facility Type												Total	
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
General TB Information														
4.4.1 Test Results	10	45.5	9	25	114	42.9	4	80	22	50	1	33.3	160	42.6
Verbally	4	40	5	55.6	69	60.5	2	50	8	36.4	1	100	89	55.6
Written	0	0	0	0	1	0.9	0	0	3	13.6	0	0	4	2.5
Both	6	60	4	44.4	44	38.6	2	50	11	50	0	0	67	41.9
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0

4.4.2 What the test results mean	10	45.5	9	25	96	36.1	4	80	20	45.5	1	33.3	140	37.2
Verbally	6	60	5	55.6	72	75	2	50	14	70	1	100	100	71.4
Written	0	0	0	0	0	0	0	0	2	10	0	0	2	1.4
Both	4	40	4	44.4	24	25	2	50	4	20	0	0	38	27.1
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.3 How TB is spread to others	16	72.7	23	63.9	169	63.5	3	60	25	56.8	1	33.3	237	63
Verbally	13	81.3	13	56.5	114	67.5	0	0	18	72	1	100	159	67.1
Written	0	0	1	4.3	1	0.6	0	0	0	0	0	0	2	0.8
Both	3	18.8	9	39.1	54	32	3	100	7	28	0	0	76	32.1
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.4 That TB can be cured	13	59.1	17	47.2	137	51.5	3	60	16	36.4	2	66.7	188	50
Verbally	11	84.6	11	64.7	98	71.5	1	33.3	11	68.8	2	100	134	71.3
Written	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Both	2	15.4	6	35.3	39	28.5	2	66.7	5	31.3	0	0	54	28.7
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TB Treatment Information														
4.4.5 The need for a treatment supporter	7	31.8	7	19.4	57	21.4	1	20	4	9.1	1	33.3	77	20.5
Verbally	5	71.4	7	100	49	86	1	100	4	100	1	100	67	87
Written	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Both	2	28.6	0	0	8	14	0	0	0	0	0	0	10	13
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.6 How long treatment will last	14	63.6	17	47.2	154	57.9	4	80	22	50	1	33.3	212	56.4
Verbally	12	85.7	13	76.5	114	74	2	50	14	63.6	1	100	156	73.6
Written	0	0	0	0	1	0.6	0	0	0	0	0	0	1	0.5
Both	2	14.3	4	23.5	39	25.3	2	50	8	36.4	0	0	55	25.9
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.7 The treatment phase they are in	9	40.9	9	25	139	52.3	4	80	20	45.5	2	66.7	183	48.7
Verbally	6	66.7	7	77.8	101	72.7	2	50	12	60	2	100	130	71
Written	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Both	3	33.3	2	22.2	38	27.3	2	50	8	40	0	0	53	29
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.8 Treatment status or progress	10	45.5	14	38.9	128	48.1	4	80	19	43.2	0	0	175	46.5
Verbally	9	90	11	78.6	102	79.7	3	75	16	84.2	0	0	141	80.6
Written	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Both	1	10	3	21.4	26	20.3	1	25	3	15.8	0	0	34	19.4
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.9 Importance of taking medications regularly	13	59.1	34	94.4	205	77.1	4	80	29	65.9	1	33.3	286	76.1
Verbally	11	84.6	30	88.2	169	82.4	3	75	26	89.7	1	100	240	83.9
Written	0	0	0	0	1	0.5	0	0	0	0	0	0	1	0.3
Both	2	15.4	4	11.8	35	17.1	1	25	3	10.3	0	0	45	15.7
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.10 How the medications should be taken, e.g., dosage, frequency, etc.	12	54.5	30	83.3	196	73.7	4	80	30	68.2	0	0	272	72.3
Verbally	5	41.7	22	73.3	135	68.9	2	50	21	70	0	0	185	68
Written	0	0	0	0	1	0.5	0	0	1	3.3	0	0	2	0.7
Both	7	58.3	8	26.7	60	30.6	2	50	8	26.7	0	0	85	31.3
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.11 Importance of taking medications for the full course of treatment	10	45.5	26	72.2	194	72.9	4	80	25	56.8	2	66.7	261	69.4
Verbally	10	100	22	84.6	159	82	2	50	19	76	2	100	214	82
Written	0	0	0	0	1	0.5	0	0	1	4	0	0	2	0.8
Both	0	0	4	15.4	34	17.5	2	50	5	20	0	0	45	17.2
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.12 Options available for treatment support, e.g., DOT	2	9.1	6	16.7	56	21.1	1	20	8	18.2	0	0	73	19.4
Verbally	2	100	5	83.3	44	78.6	0	0	7	87.5	0	0	58	79.5
Written	0	0	0	0	1	1.8	0	0	0	0	0	0	1	1.4
Both	0	0	1	16.7	11	19.6	1	100	1	12.5	0	0	14	19.2
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.13 What to do if they run out of their medication	3	13.6	7	19.4	97	36.5	2	40	12	27.3	1	33.3	122	32.4
Verbally	3	100	5	71.4	83	85.6	1	50	11	91.7	1	100	104	85.2
Written	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Both	0	0	2	28.6	14	14.4	1	50	1	8.3	0	0	18	14.8
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4.14 Possible side effects of TB medication	13	59.1	20	55.6	169	63.5	4	80	27	61.4	0	0	233	62
Verbally	12	92.3	16	80	135	79.9	2	50	19	70.4	0	0	184	79
Written	0	0	0	0	1	0.6	0	0	1	3.7	0	0	2	0.9
Both	1	7.7	4	20	33	19.5	2	50	7	25.9	0	0	47	20.2
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0

4.4.15 What to do if they experience side effects from the TB medication	10	45.5	18	50	137	51.5	4	80	25	56.8	0	0	194	51.6
Verbally	10	100	15	83.3	114	83.2	2	50	16	64	0	0	157	80.9
Written	0	0	0	0	1	0.7	0	0	1	4	0	0	2	1
Both	0	0	3	16.7	22	16.1	2	50	8	32	0	0	35	18
No response	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 3.3.2b

What type of information or topics, excluding TB/HIV, are discussed with patients during diagnosis and treatment visits? (n=376)	Facility Type													
	District General Hospital		District Preventive Health Center (one function)		District Health Center (two function)		CDC		Lung Hospital		Provincial General Hospital		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
General TB Information														
4.4.1 Test Results	10	45.5	9	25	114	42.9	4	80	22	50	1	33.3	160	42.6
4.4.2 What the test results mean	10	45.5	9	25	96	36.1	4	80	20	45.5	1	33.3	140	37.2
4.4.3 How TB is spread to other	16	72.7	23	63.9	169	63.5	3	60	25	56.8	1	33.3	237	63
4.4.4 That TB can be cured	13	59.1	17	47.2	137	51.5	3	60	16	36.4	2	66.7	188	50
TB Treatment Information														
4.4.5 The need for a treatment supporter	7	31.8	7	19.4	57	21.4	1	20	4	9.1	1	33.3	77	20.5
4.4.6 How long treatment will last	14	63.6	17	47.2	154	57.9	4	80	22	50	1	33.3	212	56.4
4.4.7 The treatment phase they are in	9	40.9	9	25	139	52.3	4	80	20	45.5	2	66.7	183	48.7
4.4.8 Treatment status or progress	10	45.5	14	38.9	128	48.1	4	80	19	43.2	0	0	175	46.5
4.4.9 Importance of taking medications regularly	13	59.1	34	94.4	205	77.1	4	80	29	65.9	1	33.3	286	76.1
4.4.10 How the medications should be taken, e.g., dosage, frequency, etc.	12	54.5	30	83.3	196	73.7	4	80	30	68.2	0	0	272	72.3
4.4.11 Importance of taking medications for the full course of treatment	10	45.5	26	72.2	194	72.9	4	80	25	56.8	2	66.7	261	69.4
4.4.12 Options available for treatment support, e.g., DOT	2	9.1	6	16.7	56	21.1	1	20	8	18.2	0	0	73	19.4
4.4.13 What to do if they run out of their medication	3	13.6	7	19.4	97	36.5	2	40	12	27.3	1	33.3	122	32.4
4.4.14 Possible side effects of TB medication	13	59.1	20	55.6	169	63.5	4	80	27	61.4	0	0	233	62
4.4.15 What to do if they experience side effects from the TB medication	10	45.5	18	50	137	51.5	4	80	25	56.8	0	0	194	51.6

3.3.3. Information provided to TB patients (patient perspective)

Table 3.3.3a

Table 5.5.5a

During your visits to this health facility, what information about this disease and its treatment were shared with you by the health workers?	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
7.1 How the disease is spread to others						
No	122	19	5	9.1	127	18.2
Yes, prompted	330	51.5	35	63.6	365	52.4
Yes, unprompted	188	29.3	15	27.3	203	29.2
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
7.2 Cough hygiene, i.e., how to reduce the risk of making others sick by covering your mouth when you cough						
No	56	8.7	1	1.8	57	8.2
Yes, prompted	371	57.9	35	63.6	406	58.3
Yes, unprompted	213	33.2	19	34.5	232	33.3
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
7.3 That this disease can be cured						
No	62	9.7	4	7.3	66	9.5
Yes, prompted	468	73	42	76.4	510	73.3
Yes, unprompted	108	16.8	8	14.5	116	16.7
No response	3	0.5	1	1.8	4	0.6
Total	641	100	55	100	696	100
7.4 How long your treatment will last						
No	55	8.6	2	3.6	57	8.2
Yes, prompted	451	70.4	39	70.9	490	70.4
Yes, unprompted	133	20.7	14	25.5	147	21.1
No response	2	0.3	0	0	2	0.3
Total	641	100	55	100	696	100

7.5 Danger signs of the disease getting worse						
No	173	27	12	21.8	185	26.6
Yes, prompted	419	65.4	38	69.1	457	65.7
Yes, unprompted	46	7.2	5	9.1	51	7.3
No response	3	0.5	0	0	3	0.4
Total	641	100	55	100	696	100
7.6 The importance of taking the medicines regularly						
No	30	4.7	2	3.6	32	4.6
Yes, prompted	253	39.5	17	30.9	270	38.8
Yes, unprompted	357	55.7	35	63.6	392	56.3
No response	1	0.2	1	1.8	2	0.3
Total	641	100	55	100	696	100
7.7 Side effects of the medicine						
No	116	18.1	5	9.1	121	17.4
Yes, prompted	395	61.6	38	69.1	433	62.2
Yes, unprompted	129	20.1	12	21.8	141	20.3
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
7.8 What to do if you have side effects from the medicine						
No	149	23.2	8	14.5	157	22.6
Yes, prompted	387	60.4	41	74.5	428	61.5
Yes, unprompted	103	16.1	5	9.1	108	15.5
No response	2	0.3	1	1.8	3	0.4
Total	641	100	55	100	696	100
7.9 The need for the sputum tests at given points during your treatment						
No	101	15.8	5	9.1	106	15.2
Yes, prompted	490	76.4	46	83.6	536	77
Yes, unprompted	48	7.5	3	5.5	51	7.3
No response	2	0.3	1	1.8	3	0.4
Total	641	100	55	100	696	100
7.10 The importance of taking the medicines through the end of treatment						
No	36	5.6	1	1.8	37	5.3

Yes, prompted	345	53.8	28	50.9	373	53.6
Yes, unprompted	258	40.2	25	45.5	283	40.7
No response	2	0.3	1	1.8	3	0.4
Total	641	100	55	100	696	100
7.11 When to come back for the next care visit for this disease						
No	58	9	1	1.8	59	8.5
Yes, prompted	504	78.6	46	83.6	550	79
Yes, unprompted	77	12	7	12.7	84	12.1
No response	2	0.3	1	1.8	3	0.4
Total	641	100	55	100	696	100
7.12 Do you have materials (e.g., pamphlets) from the health facility to remind you of the treatment information provided in the provider or other facility staff?						
No	347	54.1	23	41.8	370	53.2
Yes	291	45.4	32	58.2	323	46.4
No response	3	0.5	0	0	3	0.4
Total	641	100	55	100	696	100

3.3.4. Treatment Supporters

Table 3.3.4a

	Type of TB				Total	
	Yes, DS TB		Yes, DR TB			
	No.	%	No.	%	No.	%
4.4 Who primarily supervises your treatment, i.e., who is your treatment partner?						
Health worker at this facility	229	35.7	14	25.5	243	34.9
Community-based workers or volunteers	21	3.3	4	7.3	25	3.6
Family	243	37.9	20	36.4	263	37.8
Other (specify)	148	23.1	17	30.9	165	23.7
Total	641	100	55	100	696	100

3.4. Patient Knowledge of TB

3.4.1. Cause, Modes of Transmission, and Risk Factors of TB

Table 3.4.1a

Table 5.12a

What do you think causes this disease or spreads it from one person to another?	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
5.2.1. Microbes/germs/bacteria						
No	57	8.9	3	5.5	60	8.6
Yes, prompted	383	59.8	38	69.1	421	60.5
Yes, unprompted	78	12.2	6	10.9	84	12.1
Don't know	123	19.2	7	12.7	130	18.7
No response	0	0	1	1.8	1	0.1
Total	641	100	55	100	696	100
5.2.2. Infected person coughing or sneezing						
No	48	7.5	2	3.6	50	7.2
Yes, prompted	317	49.5	30	54.5	347	49.9
Yes, unprompted	241	37.6	21	38.2	262	37.6
Don't know	35	5.5	2	3.6	37	5.3
Total	641	100	55	100	696	100
5.2.3 Crowded living conditions						
No	95	14.8	8	14.5	103	14.8
Yes, prompted	391	61	33	60	424	60.9
Yes, unprompted	101	15.8	9	16.4	110	15.8
Don't know	54	8.4	5	9.1	59	8.5
Total	641	100	55	100	696	100
5.2.4 Blood transfusions						
No	283	44.1	24	43.6	307	44.1
Yes, prompted	209	32.6	18	32.7	227	32.6
Yes, unprompted	6	0.9	0	0	6	0.9
Don't know	143	22.3	13	23.6	156	22.4
Total	641	100	55	100	696	100
5.2.5 Sharing utensils						

No	89	13.9	6	10.9	95	13.6
Yes, prompted	398	62.1	36	65.5	434	62.4
Yes, unprompted	124	19.3	12	21.8	136	19.5
Don't know	29	4.5	1	1.8	30	4.3
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
5.2.6 Touching a person with TB						
No	384	59.9	31	56.4	415	59.6
Yes, prompted	175	27.3	14	25.5	189	27.2
Yes, unprompted	30	4.7	5	9.1	35	5
Don't know	51	8	5	9.1	56	8
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
5.2.7 Through food						
No	151	23.6	8	14.5	159	22.8
Yes, prompted	311	48.5	28	50.9	339	48.7
Yes, unprompted	139	21.7	15	27.3	154	22.1
Don't know	40	6.2	4	7.3	44	6.3
Total	641	100	55	100	696	100
5.2.8 Mosquito bites						
No	373	58.2	34	61.8	407	58.5
Yes, prompted	167	26.1	8	14.5	175	25.1
Yes, unprompted	2	0.3	0	0	2	0.3
Don't know	99	15.4	13	23.6	112	16.1
Total	641	100	55	100	696	100
5.2.9 Sexual contact						
No	315	49.1	29	52.7	344	49.4
Yes, prompted	179	27.9	11	20	190	27.3
Yes, unprompted	3	0.5	1	1.8	4	0.6
Don't know	143	22.3	14	25.5	157	22.6
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100

Table 3.4.1b

Table 5.7.1b

What do you think makes a person more at risk of getting TB?	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
5.3.1 Way of living (lifestyle)						
No	119	18.6	14	25.5	133	19.1
Yes, prompted	330	51.5	23	41.8	353	50.7
Yes, unprompted	147	22.9	13	23.6	160	23
Don't know	45	7	5	9.1	50	7.2
Total	641	100	55	100	696	100
5.3.2 Smoking						
No	51	8	6	10.9	57	8.2
Yes, prompted	402	62.7	34	61.8	436	62.6
Yes, unprompted	163	25.4	13	23.6	176	25.3
Don't know	25	3.9	2	3.6	27	3.9
Total	641	100	55	100	696	100
5.3.3 Alcohol drinking						
No	138	21.5	13	23.6	151	21.7
Yes, prompted	378	59	30	54.5	408	58.6
Yes, unprompted	78	12.2	9	16.4	87	12.5
Don't know	47	7.3	3	5.5	50	7.2
Total	641	100	55	100	696	100
5.3.4 Fatigue						
No	74	11.5	6	10.9	80	11.5
Yes, prompted	396	61.8	34	61.8	430	61.8
Yes, unprompted	134	20.9	11	20	145	20.8
Don't know	37	5.8	4	7.3	41	5.9
Total	641	100	55	100	696	100
5.3.5 Malnutrition						
No	91	14.2	9	16.4	100	14.4
Yes, prompted	414	64.6	38	69.1	452	64.9

Yes, unprompted	93	14.5	6	10.9	99	14.2
Don't know	43	6.7	2	3.6	45	6.5
Total	641	100	55	100	696	100
5.3.6 Unhygienic practices						
No	73	11.4	10	18.2	83	11.9
Yes, prompted	430	67.1	36	65.5	466	67
Yes, unprompted	92	14.4	7	12.7	99	14.2
Don't know	46	7.2	2	3.6	48	6.9
Total	641	100	55	100	696	100
5.3.7 Poor ventilation						
No	83	12.9	13	23.6	96	13.8
Yes, prompted	409	63.8	33	60	442	63.5
Yes, unprompted	89	13.9	4	7.3	93	13.4
Don't know	60	9.4	5	9.1	65	9.3
Total	641	100	55	100	696	100
5.3.8 Pollution						
No	53	8.3	7	12.7	60	8.6
Yes, prompted	410	64	40	72.7	450	64.7
Yes, unprompted	136	21.2	4	7.3	140	20.1
Don't know	42	6.6	4	7.3	46	6.6
Total	641	100	55	100	696	100
5.3.9 Being HIV infected						
No	117	18.3	9	16.4	126	18.1
Yes, prompted	349	54.4	29	52.7	378	54.3
Yes, unprompted	12	1.9	1	1.8	13	1.9
Don't know	162	25.3	16	29.1	178	25.6
No response	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
5.3.10 Contact with or living with someone who has this disease						
No	51	8	2	3.6	53	7.6
Yes, prompted	405	63.2	38	69.1	443	63.6
Yes, unprompted	152	23.7	14	25.5	166	23.9

Don't know	33	5.1	1	1.8	34	4.9
Total	641	100	55	100	696	100
5.3.11 Inherited						
No	213	33.2	18	32.7	231	33.2
Yes, prompted	343	53.5	31	56.4	374	53.7
Yes, unprompted	27	4.2	1	1.8	28	4
Don't know	58	9	5	9.1	63	9.1
Total	641	100	55	100	696	100

Table 3.4.1c

TB Patient knowledge of TB treatment	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
5.6 What is the usual time or typical period for treating drug susceptible TB?						
2 months	8	1.2	0	0	8	1.1
3 months	9	1.4	1	1.8	10	1.4
4 months	9	1.4	0	0	9	1.3
5 months	6	0.9	0	0	6	0.9
6 months	544	84.9	41	74.5	585	84.1
7 months	4	0.6	1	1.8	5	0.7
8 months	15	2.3	0	0	15	2.2
9 months	6	0.9	3	5.5	9	1.3
10 months	1	0.2	0	0	1	0.1
12 months	8	1.2	1	1.8	9	1.3
Don't know	30	4.7	7	12.7	37	5.3
No response	1	0.2	1	1.8	2	0.3
Total	641	100	55	100	696	100
5.7 What is the usual time or typical period for treating drug-resistant TB?						
0 months	5	0.8	0	0	5	0.7
1 month	1	0.2	0	0	1	0.1
2 months	5	0.8	0	0	5	0.7

3 months	3	0.5	0	0	3	0.4
4 months	1	0.2	0	0	1	0.1
5 months	1	0.2	0	0	1	0.1
6 months	45	7	0	0	45	6.5
7months	1	0.2	0	0	1	0.1
8 months	29	4.5	2	3.6	31	4.5
9 months	44	6.9	23	41.8	67	9.6
10 months	5	0.8	0	0	5	0.7
12 months	107	16.7	6	10.9	113	16.2
18 months	13	2	11	20	24	3.4
20 months	1	0.2	5	9.1	6	0.9
22 months	0	0	1	1.8	1	0.1
24 months	4	0.6	3	5.5	7	1
36 months	2	0.3	0	0	2	0.3
Don't know	357	55.7	4	7.3	361	51.9
No response	17	2.7	0	0	17	2.4
Total	641	100	55	100	696	100

3.4.2. TB Symptoms

Table 3.4.2a

Can you tell me what symptoms a person with this disease will have?	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
5.1.1 Chronic cough (more than 3 weeks)						
No	43	6.7	3	5.5	46	6.6
Yes, prompted	141	22	11	20	152	21.8
Yes, unprompted	438	68.3	39	70.9	477	68.5
Don't know	19	3	2	3.6	21	3
Total	641	100	55	100	696	100
5.1.2 Coughing up mucus or phlegm						
No	75	11.7	9	16.4	84	12.1
Yes, prompted	333	52	23	41.8	356	51.1

Yes, unprompted	200	31.2	21	38.2	221	31.8
Don't know	33	5.1	2	3.6	35	5
Total	641	100	55	100	696	100
5.1.3 Blood-streaked mucus or sputum						
No	191	29.8	19	34.5	210	30.2
Yes, prompted	293	45.7	21	38.2	314	45.1
Yes, unprompted	89	13.9	8	14.5	97	13.9
Don't know	68	10.6	7	12.7	75	10.8
Total	641	100	55	100	696	100
5.1.4 Unexplained weight loss						
No	80	12.5	5	9.1	85	12.2
Yes, prompted	392	61.2	35	63.6	427	61.4
Yes, unprompted	119	18.6	11	20	130	18.7
Don't know	50	7.8	4	7.3	54	7.8
Total	641	100	55	100	696	100
5.1.5 Fever and/or chills						
No	125	19.5	6	10.9	131	18.8
Yes, prompted	279	43.5	20	36.4	299	43
Yes, unprompted	194	30.3	25	45.5	219	31.5
Don't know	43	6.7	3	5.5	46	6.6
No response	0	0	1	1.8	1	0.1
Total	641	100	55	100	696	100
5.1.6 Night sweats						
No	182	28.4	18	32.7	200	28.7
Yes, prompted	318	49.6	26	47.3	344	49.4
Yes, unprompted	42	6.6	3	5.5	45	6.5
Don't know	99	15.4	8	14.5	107	15.4
Total	641	100	55	100	696	100
5.1.7 Persistent shortness of breath						
No	136	21.2	10	18.2	146	21
Yes, prompted	333	52	30	54.5	363	52.2
Yes, unprompted	134	20.9	12	21.8	146	21

Don't know	38	5.9	3	5.5	41	5.9
Total	641	100	55	100	696	100
5.1.8 Tiredness/fatigue						
No	64	10	5	9.1	69	9.9
Yes, prompted	340	53	27	49.1	367	52.7
Yes, unprompted	217	33.9	23	41.8	240	34.5
Don't know	20	3.1	0	0	20	2.9
Total	641	100	55	100	696	100
5.1.9 Pain in the chest or back						
No	107	16.7	8	14.5	115	16.5
Yes, prompted	347	54.1	35	63.6	382	54.9
Yes, unprompted	151	23.6	9	16.4	160	23
Don't know	36	5.6	3	5.5	39	5.6
Total	641	100	55	100	696	100
5.1.10 Other (specify)						
No	590	92	48	87.3	638	91.7
Yes, prompted	2	0.3	0	0	2	0.3
Yes, unprompted	44	6.9	6	10.9	50	7.2
Don't know	5	0.8	1	1.8	6	0.9
Total	641	100	55	100	696	100

3.4.3. Side Effects of TB Drugs

Table 3.4.3a

Table 3.1.3a

What are the possible side effects patients may experience from using or taking medicines for this disease?	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
5.4.1 Nausea						
No	270	42.1	9	16.4	279	40.1
Yes, prompted	232	36.2	32	58.2	264	37.9
Yes, unprompted	85	13.3	12	21.8	97	13.9
Don't know	54	8.4	2	3.6	56	8
Total	641	100	55	100	696	100
5.4.2 Vomiting						
No	297	46.3	15	27.3	312	44.8
Yes, prompted	230	35.9	28	50.9	258	37.1
Yes, unprompted	63	9.8	10	18.2	73	10.5
Don't know	51	8	2	3.6	53	7.6
Total	641	100	55	100	696	100
5.4.3 Loss of appetite						
No	181	28.2	6	10.9	187	26.9
Yes, prompted	336	52.4	37	67.3	373	53.6
Yes, unprompted	105	16.4	10	18.2	115	16.5
Don't know	19	3	2	3.6	21	3
Total	641	100	55	100	696	100
5.4.4 Discolored urine or tears						
No	81	12.6	9	16.4	90	12.9
Yes, prompted	502	78.3	44	80	546	78.4
Yes, unprompted	38	5.9	1	1.8	39	5.6
Don't know	20	3.1	1	1.8	21	3
Total	641	100	55	100	696	100
5.4.5 Fever						
No	323	50.4	28	50.9	351	50.4
Yes, prompted	231	36	23	41.8	254	36.5

Yes, unprompted	45	7	1	1.8	46	6.6
Don't know	42	6.6	3	5.5	45	6.5
Total	641	100	55	100	696	100
5.4.6 Yellowish eyes						
No	340	53	27	49.1	367	52.7
Yes, prompted	204	31.8	22	40	226	32.5
Yes, unprompted	22	3.4	1	1.8	23	3.3
Don't know	75	11.7	5	9.1	80	11.5
Total	641	100	55	100	696	100
5.4.7 Problems with eyesight						
No	265	41.3	12	21.8	277	39.8
Yes, prompted	287	44.8	31	56.4	318	45.7
Yes, unprompted	32	5	6	10.9	38	5.5
Don't know	57	8.9	6	10.9	63	9.1
Total	641	100	55	100	696	100
5.4.8 Joint pain						
No	241	37.6	11	20	252	36.2
Yes, prompted	289	45.1	36	65.5	325	46.7
Yes, unprompted	62	9.7	8	14.5	70	10.1
Don't know	49	7.6	0	0	49	7
Total	641	100	55	100	696	100
5.4.9 Rash						
No	283	44.1	26	47.3	309	44.4
Yes, prompted	199	31	19	34.5	218	31.3
Yes, unprompted	116	18.1	6	10.9	122	17.5
Don't know	43	6.7	4	7.3	47	6.8
Total	641	100	55	100	696	100
5.4.10 Fatigue						
No	100	15.6	8	14.5	108	15.5
Yes, prompted	300	46.8	25	45.5	325	46.7
Yes, unprompted	229	35.7	22	40	251	36.1
Don't know	12	1.9	0	0	12	1.7

Total	641	100	55	100	696	100
5.4.11 Itchy skin						
No			14	25.5	14	25.5
Yes, prompted			26	47.3	26	47.3
Yes, unprompted			13	23.6	13	23.6
Don't know			2	3.6	2	3.6
Total			55	100	55	100
5.4.12 Darkening of skin						
No			6	10.9	6	10.9
Yes, prompted			34	61.8	34	61.8
Yes, unprompted			12	21.8	12	21.8
Don't know			3	5.5	3	5.5
Total			55	100	55	100
5.4.13 Tinnitus (i.e. ringing noise in the ear(s))						
No			17	30.9	17	30.9
Yes, prompted			35	63.6	35	63.6
Yes, unprompted			2	3.6	2	3.6
Don't know			1	1.8	1	1.8
Total			55	100	55	100
5.4.14 Numbness in limbs						
No			14	25.5	14	25.5
Yes, prompted			38	69.1	38	69.1
Yes, unprompted			2	3.6	2	3.6
No response			1	1.8	1	1.8
Total			55	100	55	100
5.4.15 Other						
No	463	72.2	40	72.7	503	72.3
Yes, prompted	15	2.3	0	0	15	2.2
Yes, unprompted	159	24.8	15	27.3	174	25
Don't know	4	0.6	0	0	4	0.6
Total	641	100	55	100	696	100

3.5. TB Stigma

Table 3.5a

How are you treated by others at this facility, where 1 is strongly disagree and 5 is strongly agree?	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
6.1 Overall, I feel welcome in this health facility						
Strongly agree	283	44.1	28	50.9	311	44.7
Agree	328	51.2	27	49.1	355	51
Neither agree nor disagree	29	4.5	0	0	29	4.2
Disagree	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
6.2 Overall, healthcare providers here treat me with respect.						
Strongly agree	292	45.6	25	45.5	317	45.5
Agree	333	52	27	49.1	360	51.7
Neither agree nor disagree	15	2.3	3	5.5	18	2.6
Disagree	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
6.3 Overall, the healthcare providers are friendly to me.						
Strongly agree	291	45.4	23	41.8	314	45.1
Agree	323	50.4	30	54.5	353	50.7
Neither agree nor disagree	25	3.9	2	3.6	27	3.9
Disagree	2	0.3	0	0	2	0.3
Total	641	100	55	100	696	100
6.4 Overall, the healthcare providers treat me the same way I am treated when I receive care for other illnesses.						
Strongly agree	267	41.7	22	40	289	41.5
Agree	348	54.3	28	50.9	376	54
Neither agree nor disagree	23	3.6	4	7.3	27	3.9
Disagree	3	0.5	0	0	3	0.4
Strongly disagree	0	0	1	1.8	1	0.1
Total	641	100	55	100	696	100
6.5 Healthcare providers here turn their face away when speaking with me.						
Strongly agree	1	0.2	0	0	1	0.1

Agree	23	3.6	1	1.8	24	3.4
Neither agree nor disagree	17	2.6	3	5.5	20	2.9
Disagree	387	60.4	29	52.7	416	59.8
Strongly disagree	213	33.2	22	40	235	33.8
Total	641	100	55	100	696	100
6.6 People within this facility show discriminatory attitudes toward me because of my disease.						
Strongly agree	2	0.3	0	0	2	0.3
Agree	10	1.6	1	1.8	11	1.6
Neither agree nor disagree	7	1.1	1	1.8	8	1.1
Disagree	369	57.6	29	52.7	398	57.2
Strongly disagree	253	39.5	24	43.6	277	39.8
Total	641	100	55	100	696	100
6.7 Overall, I feel distressed, intimidated, or offended when interacting with healthcare providers at this facility.						
Strongly agree	2	0.3	0	0	2	0.3
Agree	6	0.9	0	0	6	0.9
Neither agree nor disagree	7	1.1	1	1.8	8	1.1
Disagree	356	55.5	25	45.5	381	54.7
Strongly disagree	270	42.1	29	52.7	299	43
Total	641	100	55	100	696	100

3.6. Patient Barriers to Accessing TB Care

Table 3.6a

Next, I would like to ask you about the costs of the care for your disease	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
11.1 Have you ever been unable to come to the health facility because of the cost?						
No	617	96.3	54	98.2	671	96.4
Yes	22	3.4	1	1.8	23	3.3
No response	2	0.3	0	0	2	0.3
Total	641	100	55	100	696	100

11.2 Do you have to pay to see a healthcare provider at this facility?						
No	450	70.2	47	85.5	497	71.4
Yes	189	29.5	8	14.5	197	28.3
No response	2	0.3	0	0	2	0.3
Total	641	100	55	100	696	100

Table 3.6b

Next, I want to ask if you have received certain tests at this facility, and if so, I will ask if you have to pay for them.	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB		No.	%
	No.	%	No.	%	No.	%
11.3 (a) Sputum tests						
No	193	30.1	12	21.8	205	29.5
Yes	444	69.3	43	78.2	487	70
No response	4	0.6	0	0	4	0.6
Total	641	100	55	100	696	100
11.3 (b) Sputum tests						
No	346	77.9	38	88.4	384	78.9
Yes	95	21.4	5	11.6	100	20.5
No response	3	0.7	0	0	3	0.6
Total	444	100	43	100	487	100
11.4 (a) Blood tests						
No	288	44.9	19	34.5	307	44.1
Yes	349	54.4	36	65.5	385	55.3
No response	4	0.6	0	0	4	0.6
Total	641	100	55	100	696	100
11.4 (b) Blood tests						
No	229	65.6	30	83.3	259	67.3
Yes	117	33.5	6	16.7	123	31.9
No response	3	0.9	0	0	3	0.8
Total	349	100	36	100	385	100
11.5 (a) Chest X-rays						
No	329	51.3	19	34.5	348	50

Yes	307	47.9	36	65.5	343	49.3
No response	5	0.8	0	0	5	0.7
Total	641	100	55	100	696	100
11.5 (b) Chest X-rays						
No	206	67.1	31	86.1	237	69.1
Yes	98	31.9	5	13.9	103	30
No response	3	1	0	0	3	0.9
Total	307	100	36	100	343	100

3.7. Patient Satisfaction with TB Services

3.7.1. Patient Perspective of TB Services offered by Health Facility

Table 3.7.1a

	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
Now I would like to ask you about your experience with this facility in general. (n=696)						
12.1 During your visits to this facility, do you find the clinic area to be clean?	626	97.7	55	100	681	97.8
12.2 Are there enough comfortable places to sit?	630	98.3	55	100	685	98.4
12.3 During your visits to this facility, is drinkable water usually available?	429	66.9	36	65.5	465	66.8
12.4 During your visits to this facility, are the toilets usually clean?	465	72.5	47	85.5	512	73.6
12.4.1 During your visits to this facility, are the toilets always usable?	466	95.5	47	100	513	95.9

Table 3.7.1b

Table 3.7.1b						
	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
Now I would like to ask you about your experience with this facility in general. (n=696)						
3.1 Do you always talk to the same healthcare providers every time you visit this facility?	600	93.6	49	89.1	649	93.2
3.2 Do you have difficulties in getting care for your disease in this facility because of a language barrier?	45	7	2	3.6	47	6.8

3.3 Have you ever been turned away from receiving care for your disease during official working hours at this facility?	27	4.2	2	3.6	29	4.2
3.4.1 Are the medicines always available?	560	87.4	40	72.7	600	86.2
3.4.2 Are you told how to take the medicines each time you collect them?	536	95.7	38	95	574	95.7
3.4.3 Have you been given written instructions on how to take your prescribed drugs?	550	98.2	40	100	590	98.3
3.5 Has a healthcare provider at this facility talked with you about quitting smoking?	497	88.8	37	92.5	534	89
3.6 Are the clinic hours convenient for you?	97	89.8	6	60	103	87.3
3.7 Are the waiting time(s) before talking to healthcare providers at this facility generally acceptable to you?	639	99.7	55	100	694	99.7

3.7.2. General Satisfaction

Table 3.7.2a

	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
14.1 Overall, how satisfied are you with the TB care you have received at this facility so far?						
Very dissatisfied	11	1.7	0	0	11	1.6
Dissatisfied	7	1.1	0	0	7	1
Neither satisfied nor dissatisfied	30	4.7	1	1.8	31	4.5
Satisfied	297	46.3	20	36.4	317	45.5
Very satisfied	296	46.2	34	61.8	330	47.4
Total	641	100	55	100	696	100

4 Outcome Indicators

4.1. Timing of Care Seeking, Diagnosis and Treatment Initiation

Table 4.1a

	Type of TB				Total	
	Yes, DS_TB		Yes, DR_TB			
	No.	%	No.	%	No.	%
2.1 How long after you first started having symptoms, such as coughing, did you go to the clinic?						
Within 1 week	168	26.2	15	27.3	183	26.3
1-2 weeks	81	12.6	6	10.9	87	12.5
More than 2 weeks	320	49.9	30	54.5	350	50.3
No symptoms/TB diagnosed during through periodic examination	67	10.5	3	5.5	70	10.1
Don't know	5	0.8	1	1.8	6	0.9
Total	641	100	55	100	696	100
2.2 When you found out that you might have this disease, where did you get tested?						
At this clinic	171	26.7	23	41.8	194	27.9
At a different clinic	470	73.3	32	58.2	502	72.1
Total	641	100	55	100	696	100
2.3 How long after you were tested (e.g., chest X-ray, sputum test, etc.) were you told you had this disease?						
Within two days	426	66.5	35	63.6	461	66.2
Within one week	143	22.3	14	25.5	157	22.6
1-2 weeks	37	5.8	4	7.3	41	5.9
More than 2 weeks	31	4.8	0	0	31	4.5
Don't know	4	0.6	2	3.6	6	0.9
Total	641	100	55	100	696	100
2.4 How long after you were told you had this disease did you start treatment?						
Within 2 days	532	83	36	65.5	568	81.6
Within one week	87	13.6	12	21.8	99	14.2
1-2 weeks	14	2.2	4	7.3	18	2.6
More than 2 weeks	7	1.1	3	5.5	10	1.4
Don't know	1	0.2	0	0	1	0.1
Total	641	100	55	100	696	100
2.5 How long have you been on treatment?						
Less than 2 months	164	25.6	1	1.8	165	23.7
2-4 months	225	35.1	0	0	225	32.3

4-7 months	236	36.8	24	43.6	260	37.4
7-10 months	10	1.6	21	38.2	31	4.5
10-24 months	5	0.8	8	14.5	13	1.9
More than 24 months	1	0.2	1	1.8	2	0.3
Total	641	100	55	100	696	100
2.6 What phase of treatment are you in now?						
Intensive	160	25	6	10.9	166	23.9
Continuation	439	68.5	45	81.8	484	69.5
Don't know	42	6.6	4	7.3	46	6.6
Total	641	100	55	100	696	100

4.2. TB Treatment Outcomes

4.2.1. DS-TB Outcomes

Table 4.2.1a

Cohort	July 1, 2021 - June 30, 2022	
	N	%
3.1.1 New DS_TB patients started treatment	12,458	
3.3.6 Cured	3,291	26.4
3.3.5 Completed treatment	7,831	62.9
3.3.2 Failed	80	0.6
3.3.3 Died	361	2.9
3.3.1 LTFU	592	4.8
3.3.4 Not evaluated	303	2.4

4.2.2. DR-TB Outcomes

Table 4.2.2a

Cohort	July 1, 2019 - June 30, 2021	
	N	%
5.1.1 New DR_TB patients started treatment	1,994	
5.1.6 Cured	1,064	53.4
5.1.7 Completed treatment	373	18.7
5.1.3 Failed	81	4.1

5.1.4 Died	172	8.6
5.1.2 LTFU	248	12.4
5.1.5 Not evaluated	56	2.8

4.3. TPT Outcomes

4.3.1. PLHIV

Table 4.3.1a

Cohort	July 1, 2021 - June 30, 2022	%
	N	
6.1.2 PLHA initiated on TPT	3,346	
6.1.3 PLHA TPT interrupted due to adverse event	18	0.5
6.1.4 PLHA on TPT died	7	0.2
6.1.5 PLHA on TPT active TB	3	0.1
6.1.6 PLHA on TPT LTFU	110	3.3
6.1.8 PLHA on TPT completed	3,208	95.9
*Includes data from 50 facilities of the 70 facilities that provided TPT for PLHA		

4.3.2. Children under 5 years of age

Table 4.3.2b

Cohort	July 1, 2021 - June 30, 2022	%
	N	
6.2.2 Child contacts initiated on TPT	235	
6.2.3 Child contacts on TPT interrupted due to adverse event	23	9.8
6.2.4 Child contacts on TPT died	0	0
6.2.5 Child contacts on TPT active TB	0	0
6.2.6 Child contacts on TPT LTFU	10	4.3
6.2.8 Child contacts on TPT completed	202	86
*Includes data from 99 of the 111 facilities that provided TPT to child contacts of confirmed TB cases		